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ABSTRACT
Lyme disease, caused by the spirochete Borrelia burgdorferi (Bb), is the
most commonly reported vector-borne disease in the United States – with 30,000
cases being reported to the CDC annually, though it is estimated that 300,000
individuals are infected each year in the U.S [1–4]. Due to the medical treatment
of the disease, this equates to an estimated $712 million - $1.3 billion in medical
costs each year [5]. Conclusively, due to the continued geographical spread and
increasing incidence rate, Lyme disease is becoming a greater public health
threat throughout the world.
The symptoms of Lyme disease can range from erythema migrans to
more systematic disorders such as arthritis and neurological complications,
termed neuroborreliosis [6,7]. Manifestations of neuroborreliosis include
radiculoneuritis, meningitis, and facial palsy [8–10]. Interestingly, B. burgdorferi
does not produce any known toxins, and it is thought that the resulting host
immune response leads to cellular and tissue damage associated with clinical
symptoms. Although many individuals will be effectively treated through the
administration of antibiotics, up to 20% of patients will experience on-going
symptoms termed Post-treatment Lyme Disease Syndrome (PTLDS). PTLDS is
marked by persistent musculoskeletal pain and neurological complications.
Inflammatory states have been associated to these symptoms with the invasion
of peripheral immune cells and an increase of inflammatory cytokines.
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Furthermore, the neurological complications of PTLDS has been
associated with an increase in glial inflammation. It is well-documented that B.
burgdorferi is capable of penetrating into the central nervous system (CNS);
however, it is unknown how and where the bacterium does so. Additionally, the
exact pathogenetic mechanisms of neuroborreliosis and PTLDS are poorly
understood. The work within this dissertation aims to provide novel insight into
these gaps in knowledge.
This dissertation is laid out into three sections relating to understanding
the pathogenesis of the neurological effects of Lyme disease. In the first study,
we aimed to provide an explanation for the dissemination of B. burgdorferi and
peripheral immune cells into the central nervous system. Clinical presentations of
neuroborreliosis is associated with an increase of peripheral immune cells,
inflammatory chemokines, and live B. burgdorferi in the cerebrospinal fluid
(CSF). To this end, we sought to investigate a direct route from hematogenous
dissemination into the CSF. The choroid plexus (CP) is a structure within the
ventricles of the brain that is responsible for the production of CSF, the formation
of the blood-CSF barrier, and regulation of the immune response. This barrier
allows for the exchange of specific nutrients, waste, and peripheral immune cells
between the blood stream and CSF. We hypothesize that during infection of the
choroid plexus, Borrelia burgdorferi will induce an immune response conducive to
the chemotaxis of immune cells and subsequently lead to a pro-inflammatory
state within the CNS. To investigate this hypothesis, we cultured primary human
choroid plexus epithelial cells and infected with the B. burgdorferi strain B31 MI-
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16 for 48 hours. RNA was isolated and used for RNA sequencing and RT-qPCR
validation. Secreted proteins in the supernatant were analyzed via ELISA.
Transcriptome analysis based on RNA sequencing determined a total of 160
upregulated genes and 98 downregulated genes. Pathway and biological
process analysis determined a significant upregulation in immune and
inflammatory genes specifically in chemokine and interferon related pathways.
Further analysis revealed downregulation in genes related to cell to cell junctions
including tight and adherens junctions. Protein analysis of secreted factors
showed an increase in inflammatory chemokines, corresponding to our
transcriptome analysis. These data further demonstrate the role of the CP in the
modulation of the immune response in a disease state and give insight into the
mechanisms by which Borrelia burgdorferi may disseminate into, and act upon,
the CNS. Future experiments aim to detail the impact of B. burgdorferi on the
blood-CSF-barrier (BCSFB) integrity and inflammatory response within animal
models.
The second and third study aim to elucidate the pathogenic mechanisms
of neuroborreliosis and PTLDS, specifically the manifestations of a persistent
inflammatory state. As B. burgdorferi has previously been shown to elicit an
inflammatory response in astrocytes, and glial inflammation is associated with
PTLDS, we sought to investigate the epigenetic modifications associated with the
astrocytic response in order to determine a mechanistic explanation to these
disorders. In the second study, we investigated the differential DNA methylation
of astrocytes in response to three strains of B. burgdorferi – B31 MI-16, B31 e2,
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and 297 through the use of beadchip array. This study utilized primary human
astrocytes in vitro. This study was met with a limiting factor in biological replicate
variability that led to diminished results. Nevertheless, differential methylation
within specific genes involving vesicle trafficking and cell communication were
observed. This suggests that DNA methylation may be a mechanistic explanation
for the changes in gene expression of astrocytes in response to
B. burgdorferi.
In the third study, we utilized the same astrocyte model of the second
study to investigate the effects of B. burgdorferi on chromatin structure of
astrocytes. We performed in vitro infection of astrocytes with the B31 MI-16 strain
for 24, 48, 72, and 96 hours. Following infection, ATAC-seq was performed to
interrogate the chromatin structure of astrocytes in response to B. burgdorferi.
We observed a robust change in chromatin accessibility at 24-hours with 25,464
differential peaks. At 48, 72, and 96 hours, these peaks were reduced to 7,266,
3,376, and 3,015 respectively. Additionally, while many of the differential peaks
were associated with open chromatin at 24, 48, and 72 hours, the 96-hour time
point was marked by a dramatic decrease in chromatin accessibility. Many of the
peaks within gene bodies at the first three time points were associated with
changes in anatomical and morphological alterations, while the 96-hour time
point was highlighted by metabolic and cellular stress. This suggests that
astrocytes undergo an acute response following infection observed by a large
change in chromatin structure associated with inflammation and immune
response genes, which later decrease in accessibility. Motif enrichment analysis
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provides greater insight into the overall response of astrocytes across time
points. The AP-1 transcription factor is involved in the transcription of genes in
response to inflammatory stimuli, stress signals, and infection. This transcription
factor is made up of a heterodimer that includes the FOS, JUN, ATF, and JDP
families. Motif analysis indicated significant enrichment of these family members
at each time point, and in fact, analysis of peaks shared amongst all time points
indicated AP-1 motif as being the most significantly enriched. These data
suggest that the response of astrocytes to B. burgdorferi is in part due to the
changes in chromatin accessibility that provides an environment for the
transcription of genes associated with the inflammatory and immune response.
Furthermore, AP-1 has been implicated as a potential transcription factor
responsible for these changes in gene expression.
Together, the work within this dissertation demonstrates potential
mechanisms for the pathogenesis of neuroborreliosis and PTLDS. This is
highlighted by the potential of the choroid plexus as a route of dissemination for
B. burgdorferi and peripheral immune cells into the CNS as an explanation for
the clinical manifestations of neuroborreliosis. Additionally, these studies are the
first to implicate B. burgdorferi as an epimutagen which provides insight into the
mechanisms and development of the neurological and persistent symptoms of
Lyme disease. In conclusion, this work provides novel insights for the
pathogenesis of the neurological effects of Lyme disease which may aid in the
development of future therapeutics.
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CHAPTER I
AN INTRODUCTION TO LYME DISEASE
A Brief History of Lyme Disease
In 3300 BCE, a man colloquially known as Ötzi the Iceman died in the
Ötztal Alps on the Austrian-Italian border, with evidence indicating he had likely
died a violent death, and it wouldn’t be until 1991 when his body was first
discovered [6,7]. Following three decades of work and the advent of nextgeneration sequencing technologies, researchers were able to uncover a
detailed medical history of Ötzi which included musculoskeletal abnormalities
associated with arthritis and the presence of Borrelia burgdorferi (Bb) DNA from
a bone biopsy of Ötzi’s pelvis – evidence of the earliest human case of Lyme
disease [8,9]. Though the Iceman may hold the record for the first known case of
Lyme disease, he most likely was not the first individual to have contracted the
pathogen, as recent phylogenetic research in the U.S. suggests that B.
burgdorferi may have first diverged from a common ancestor 60,000 years ago
[10]. However ancient Borrelia burgdorferi may be, it wasn’t until the 1970’s when
doctors and scientists first identified Lyme disease.
In 1975 a cluster of cases originally thought to be juvenile rheumatoid
arthritis were identified in the towns of Lyme and Old Lyme, Connecticut [11].
This epidemic form of arthritis was initially investigated by Steere et al. and
1

ultimately led to the recognition of what is now known as Lyme disease [12].
Upon this investigation, it was initially suggested that a tick was the main vector
of Lyme arthritis, and in 1978 the first epidemiological evidence was found,
showing the tick, Ixodes scapularis, was the main vector for the disease [13,14].
Though the characterization of the disease and its vector were being
investigated, the infectious agent was still unknown. It was in 1982 in which
Burgdorfer and his colleagues first isolated the infectious agent, now known as
the spirochete bacterium Borrelia burgdorferi [15].
Since its discovery, Lyme disease has seen a consistent increase in the
number of reported cases in the United States, with approximately 30,000 cases
being reported each year (Figure I-1A) [16]. However, since only a small
percentage of cases are reported, the total number of individuals who contract
Lyme disease are estimated to be around 300,000 annually in the US. This
estimation comes from two studies from the Centers for Disease Control and
Prevention (CDC) that utilized clinical laboratory testing results of people who
tested positive for Lyme disease and used medical claims from insurance
databases [3,4]. These cases are not uniformly distributed throughout the US. In
fact, 93% of reported illnesses are within 15 states, concentrated within the
Northeast and upper Midwest regions, but are expanding into other states
(Figure I-1C, Table I-1) [16]. As the most reported vector-borne disease in the
US, the economic burden of medical costs are estimated to be between $712
million to $1.3 billion each year – these figures are attributed to initial testing and
treatment of Lyme disease and ongoing healthcare associated with post-
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Figure I - 1.

Incidence and geographical distribution of confirmed Lyme
disease.
An infographic of Lyme disease incidence and geographical
distribution. A) The number of reported cases in the United
States by year from 1996-2018. Changes to case definition were
made in 2008 to strengthen requirements of a confirmed case.
The definition for a confirmed case is a positive culture for B.
burgdorferi and a positive two-tier IgM or IgG serological test or a
single-tier positive IgG immunoblot. A probable case requires
evidence of infection and clinical diagnosis of Lyme disease, but
does not fully meet the confirmed disease definition. B) The
average number of confirmed cases in the US by month from
2008-2018. Peak disease onset is in June and July. C) A
geographical map of the United States indicating the distribution
of the average annual rate of confirmed Lyme disease from
2008-2015. High incidence regions are found in the Northeast
and Upper Midwest regions. Associated values for each state
can be found in Table 1-1. All data was obtained from the Center
for Disease Control and Prevention [1].

3

4

Table I - 1.

Incidence rates of confirmed Lyme disease per 100,000 individuals
in each state and district. From 2008-2015

5

treatment Lyme disease syndrome (PTLDS) [10]. Though many individuals will
recover through effective treatment, Lyme disease can lead to a wide range of
symptoms that can be long lasting and detrimental to the patient.
The Genetics of Borrelia burgdorferi
In 1997, the genomic sequence of B. burgdorferi strain B31 was
sequenced, making it the third microbial genome to be sequenced, behind
Haemophilus influenzae and Mycoplasma genitalium [17–19]. The genome of
B. burgdorferi is highly complex and quite unusual with respect to other bacterial
genomes – it consists of a nearly 1 megabase linear chromosome (~950 kb) with
a highly variable set of circular and linear plasmids that range in size from 5 kb
(linear plasmid 5, lp5) to 56 kb (lp56) [19,20]. While some plasmids are quite
evolutionarily stable (i.e. lp54, cp26), many have undergone non-homologous
and duplicative recombination, accounting for the wide diversity in plasmid
number and content [21]. The strain B31 MI was shown to contain 21 plasmids
(12 linear and 9 circular), though a recent study of 14 B. burgdorferi sensu stricto
(s.s.) strain isolates showed that the bacteria can carry between 9 and 23
plasmids [20,21].
Selective pressure from the environment in which the bacteria persists has
been shown to cause changes in plasmid content. In fact, one consideration
researchers must take is the number of in vitro passages that B. burgdorferi
undergoes, as continual cultivation can lead to loss of plasmids [22–24].
Furthermore, plasmid loss, such as lp25, has been shown to be correlated to loss
of infectivity in in vivo models, suggesting specific genes within these plasmids
6

are required for successful infection but not necessary for survival within in vitro
environments [23,25]. With regards to plasmid content, changes in gene
expression have been documented during each stage of the bacterial life cycle
from tick to host.
During its life cycle, B. burgdorferi encounters a wide range of
environments and has been observed to undergo adaptions to gene expression
in response to changes in pH, carbon dioxide, oxygen, osmolarity, and nutrients
[26–31]. The bacteria utilize two major systems to regulate the expression of
genes during its enzootic life cycle between tick and host: Rrp2-RpoN-RpoS
regulatory system and histidine kinase (Hk)1-Rrp1 two-component transduction
system (TCS). RpoS is an alternative RNA polymerase σ-factor necessary for
transcription of a large number of genes that encode proteins necessary for
transmission between the tick and host, maintenance of infection within the host,
as well as persistence within the tick [32,33]. RpoN, another alternative RNA
polymerase σ-factor, is responsible for the transcription of RpoS, which requires
an open rpoS promoter complex that is mediated by phosphorylated response
regulatory protein 2 – Rrp2 [34–36]. TCS proteins generally mediate bacterial
adaptation to their surroundings. The Hk1/Rrp1 system controls the transcription
of genes that are essential for survival during enzootic cycle transitions, that
occur during tick feeding with the uptake or deposition of B. burgdorferi [37].
Binding of ligands to the periplasmic domains of Hk1 leads to the initiation of a
signaling cascade that activates Rrp1, which in turn leads to the production of
cyclic di-GMP, a secondary messenger. Hk1/Rrp1 is required for the colonization
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of the tick midgut, and spirochetes that lack either component do not survive
[37,38].
During infection of a host, the Rrp2-RpoN-RpoS system is activated,
allowing host genes to be expressed, while inversely, genes required within the
tick are repressed. The outer surface proteins (Osps) of B. burgdorferi exemplify
these changes in gene expression. Within the host, OspC, allows for the initial
establishment of early infection, but is later repressed when no longer required to
maintain the infection. During the uptake of the bacteria from host to tick, the
Rrp2-RpoN-RpoS system is inactive, and the Hk1/Rrp1 system activates
expression of tick-phase genes such as OspA, leading to colonization of the tick
midgut via binding of Tick Receptor for OspA (TROSPA). Spirochetes that lack
OspA fail to colonize the tick and are later expelled [39–41]. During this initial tick
phase, Hk1/Rrp1 induces gene expression within the glp operon allowing for
utilization of glycerol[42]. During the unfed nymphal stage, B. burgdorferi
encounters a nutrient-deficient environment, where both Bb gene expression
systems become inactive while tick-phase genes remain expressed [34,35].
During the next blood meal, the large influx of nutrients mediates a robust
change in Bb gene expression that allows B. burgdorferi to take advantage of the
new environment. Activation of the Rrp2-RpoN-RpoS and Hk1/Rrp1 systems
provides a shift in gene expression towards mammalian infection and
transmission, respectively [35]. OspA is subsequently downregulated, allowing
for the detachment and transmission from tick to host. OspC, conversely is
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upregulated and required for the initial dissemination and immune evasion
necessary for the establishment of early infection in mammals [43,44].
The Enzootic Life Cycle of Borrelia burgdorferi
and Ixodes scapularis
B. burgdorferi sensu lato (s.l.). is primarily transmitted by four species of
Ixodes tick throughout the world: Ixodes scapularis in upper Midwestern and
Northeastern North America, Ixodes pacificus in Western North America, Ixodes
persulcatus in Asia, and Ixodes ricinus in Europe [45–47]. The life cycle of B.
burgdorferi and Ixodes scapularis is depicted in Figure I-2. There are three
stages of the tick life cycle, in which a blood meal is taken at each stage: larva,
nymph, and adult. As B. burgdorferi cannot be transovarially transmitted, the
larva hatch from eggs uninfected, requiring each generation to re-acquire the
pathogen from infected reservoir hosts [48]. Larva will typically hatch in the
spring and begin seeking a blood meal and acquire B. burgdorferi if feeding on
an infected reservoir host. Following its first blood meal, infected larva will begin
molting to the nymph stage, and retain the infection transstadially, that is, the
infection is maintained between each life stage. Nymphs will emerge in the
spring, and again, the tick will begin questing for a blood meal by climbing grass
or other tall structures to increase the likelihood of encountering a host. Though
nymphs tend to feed on small to medium animals, this provides the first
opportunity for B. burgdorferi to be transmitted to reservoir species to maintain a
constant transmission cycle or to be transmitted to dead-end hosts such as
humans. Following this feeding, the nymphs will detach and molt to adults in the
fall of the same year. At this stage, adults will find medium to large mammals to
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Figure I - 2.

The enzootic life cycle of Borrelia burgdorferi.
Ixodes scapularis, is the predominant vector for B. burgdorferi in
the United States. The life cycle of I. scapularis generally spans
two years. There is no transovarian transmission of
B. burgdorferi, thus eggs and larva are uninfected. Between
each life stage, the tick must take a blood meal. Larvae acquire
infection from feeding on an infected reservoir host. The larva
then molts to a Nymph, maintaining the infection. This is the first
stage that the tick can transmit the bacteria to a naïve host, such
as humans, leading to the onset of Lyme disease. Following a
second blood meal, the tick will mature into an adult. The adult
tick can infect another host and reestablish the reservoir of
B. burgdorferi in specific animals such as the white-footed
mouse. Ticks will mate at this stage, lay uninfected eggs, and the
cycle repeats.
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feed – a common host is Odocoileus virgiianus (white-tailed deer). Females and
males will then mate, and females will find a suitable environment to lay eggs,
thus starting the cycle again.
As illustrated, Ixodes will feed once during each stage of life. Though each
stage shows an inclination to specific hosts, the ticks are considered generalist
feeders and will feed on a wide variety of animals, including rodents, birds,
racoons, and deer [49–53]. Typically, larva and nymphs will show a propensity
towards smaller to medium mammals such as mice, shrews, or birds, while
adults will feed on larger animals like the white-tailed deer or coyotes [54,55].
Activity of I. scapularis at all stages is based on seasonality and climate, and
peak activity is observed in spring and summer, though larval activity may occur
later than nymphs or adults [45,47,56,57]. This correlates with the seasonality of
confirmed cases of Lyme disease in which peak onset of disease occurs in June
and July (Figure 1-1B).
Furthermore, while B. burgdorferi can infect a wide range of animals due
to the generalist feeding behavior of Ixodes ticks, only a few animals have been
observed to maintain a persistent infection, allowing for a natural reservoir for the
spirochete. One of the most prevalent reservoir species in North America is the
white-footed mouse Peromyscus leucopus [58–60]. Though white-foot mice can
harbor the bacteria, they do not exhibit pathology associated with Lyme disease,
suggestive of co-evolution between the species. This allows for the modulation of
the host immune response that is beneficial to the bacteria [35,61–63].
Understanding the life cycle, preferential hosts, and reservoir species for Ixodes
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scapularis and B. burgdorferi provides insight into the increasing incidence of the
disease, both in terms of the number of individuals infected and geographical
distribution.
Symptoms and Treatments: From Tick Bite to the Doctor’s Office
An overview of the symptoms can be found in Figure I-3. Lyme disease is
transmitted to humans by a tick bite, typically from Ixodes scapularis or Ixodes
pacificus on the Pacific Coast of the US [64,65]. During the initial localized stages
of the disease, the most common and indicative symptom is the erythema
migrans (EM) rash which presents in 70%-80% of infected individuals [66]. If
treated by antibiotic therapy during this early stage of the disease, most
individuals will recover. Typically, an individual will receive a course of antibiotics
such as doxycycline or cefuroxime for 2-3 weeks. If a patient does not receive
treatment during this early phase of the disease, the bacteria will disseminate via
the circulatory system into other tissues and organs. During early B. burgdorferi
dissemination throughout the body, it commonly enters joints, tendons, or
bursae. Patients may initially be asymptomatic, but during the late stages of the
disease when the innate and adaptive immune response are present, clinical
presentation of arthritis is usually seen within major joints. In a study that
followed patients with EM rash who did not receive antibiotic therapy, roughly
60% of patients developed intermittent or chronic arthritis [67]. A more recent
surveillance of reported cases by the CDC indicates that approximately 30% of
individuals will develop arthritis [66]. While most symptoms will resolve following
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Figure I - 3.

The symptoms of Lyme disease and post-treatment Lyme
disease syndrome.
Lyme disease is a multi-systemic disease. Symptom severity can
be variable but increases the longer the disease is left untreated.
Erythema migrans, also known as the bullseye rash, is a
common and indicative sign of Lyme disease, appearing in 70%
of cases. Arthritis occurs in 29% of individuals, and usually
affects major joints such as the knee. Carditis is rare,1%, but is a
serious symptom that leads to atrioventricular block, a disruption
in the electric signals of the heart. The invasion of the central
nervous system results in neuroborreliosis, with associated
symptoms including facial palsy, radiculoneuropathy, and
meningitis. Post-treatment Lyme disease syndrome occurs in up
to 20% of Lyme disease patients and is defined by the
continuation or appearance of symptoms after treatment, in
which an active infection is no longer detectable. Symptoms
include fatigue, musculoskeletal pain, depression, and cognitive
decline.
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treatment, some patients will continue to experience persistent synovial
inflammation that may last for months to years [68].
During the dissemination phase, B. burgdorferi may enter cardiac tissue
causing 1-4% of patients to develop carditis [66,69]. Involvement in cardiac
tissue can impair electrical signals between the atria and ventricles of the heart,
termed atrioventricular block [70]. Clinical manifestations of Lyme carditis present
as shortness of breath, light-headedness/fainting, heart palpitations, or chest
pains [70].
While many patients will recover from Lyme disease following an
appropriate antibiotic intervention, the pathophysiology of the disease ranges
drastically from person to person. Because B. burgdorferi does not produce or
secrete any known toxins that can be attributed to the manifestations of the
disease, it is suggested that the host immune and inflammatory response elicited
by the infection plays a major contributing factor to the pathogenesis of the
disease.
Neuroborreliosis
The involvement of the central nervous system (CNS) is usually seen in
the later stages of delayed or untreated Lyme disease but has been observed in
patients that still present with EM rash [71]. When B. burgdorferi does
disseminate into the CNS, neurological complications, termed “neuroborreliosis”,
are typically observed. Neurological manifestations include radiculoneuritis,
meningitis, and facial palsy [72–74]. It is well-documented that B. burgdorferi is
capable of penetrating the central nervous system (CNS). This is evident from
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the direct detection of the pathogen within the cerebrospinal fluid, usually
performed by lumbar puncture, followed by bacterial culture or PCR [75].
Furthermore, other methods suggest of CNS invasion - the detection of
intrathecal antibodies, an increase in peripheral immune cells, such as
lymphocytic pleocytosis, and the presence of the chemoattractant cxcl13 [76–79].
Though methods of detection and diagnosis of neuroborreliosis continue to grow,
very little is known about the mechanisms by which B. burgdorferi enters the
CNS and the pathophysiology of neuroborreliosis. Explants and primary cultures
of dorsal root ganglia tissue from rhesus macaques that were incubated with
Borrelia burgdorferi showed an increase in inflammatory cytokines ccl2, il-6, and
il-8, as well as the apoptosis of sensory neurons [80]. The correlation between
inflammation and the pathology of the disease is also observed in the
inflammation and subsequent apoptosis of oligodendrocyte cultures following Bb
infection [81]. This is further seen in the cerebrospinal fluid (CSF) of patients with
confirmed neuroborreliosis that show increases in chemokines such as ccl2, ccl5,
and cxcl1 [82–84]. The presence of these chemokines may indicate a role for
these factors in the host immune response, notably immune cell trafficking.
A major point of contention within the realm of neuroborreliosis is the
mechanism by which B. burgdorferi enters the CNS. As stated previously, the
bacteria have been found in the CSF and indeed the commonly used
B. burgdorferi 297 strain is an isolate from the CSF of a patient [85]. There are
two possible routes of dissemination into the CNS, retrogradely via peripheral
nerves or hematogenous dissemination [86]. However, it is more likely that
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dissemination occurs hematogenously, as it is the major route of dissemination to
secondary systemic organs after the establishment of localized infection[87,88].
Transportation and successful immune evasion through the bloodstream are only
half of the story. The next hurdle B. burgdorferi has to overcome to enter the
CNS is successfully passing through the blood-brain barrier. Some researchers
advocate for the penetration of endothelial cells while others argue the
transcellular migration of the spirochete [89–91]. Clearly, major work is still
required to elucidate the mechanisms of CNS entry and pathogenesis of
neuroborreliosis. One aspect of the work presented herein aims to provide an
alternative route of entry into the CNS.
Post-Treatment Lyme Disease Syndrome
Several studies have shown that the majority of patients who are treated
with antibiotics successfully recover; however, individuals presenting with late
manifestations of Lyme disease may respond more slowly to the antibiotic
therapy [92–97]. Approximately 10-20% of individuals who complete treatment
for Lyme disease experience persistent or intermittent symptoms at least 12
months post-treatment [94,98,99]. Originally named “Chronic Lyme Disease” to
describe individuals with persistent and non-specific symptoms seen in
suspected Lyme disease patients, the term has come under considerable
scrutiny for its failure in specificity and consistency for diagnosis and has since
been further refined to a more accurate term, Post-Treatment Lyme Disease
Syndrome [99]. Common symptoms of PTLDS include fatigue, sleeplessness,
joint and muscular pain, headache, paresthesia, and overall cognitive decline
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involving difficulties in memory and concentration [93,100]. PTLDS is defined as
a syndrome in which an individual with a documented diagnosis of Lyme disease
and associated symptoms, received the generally accepted treatment regimen of
antibiotics, but has shown persistent symptoms such as fatigue, musculoskeletal
pain, or cognitive deficits for at least 6 months following the completion of
treatment with no evidence of an on-going infection or co-morbidities that would
otherwise explain the individual’s symptoms [77,99,101]. The likelihood of a
PTLDS diagnosis is correlated to the delay of antibiotic treatment and therefore
the extent of B. burgdorferi dissemination into other tissue such as the joints or
central nervous system [102,103].
Currently, there are no effective treatments for PTLDS or strict guidelines
for clinical care. The complexity of the biological systems involved in PTLDS (i.e.
CNS, musculoskeletal), the generality of symptoms (i.e. pain, cognitive decline),
and on-going controversy worsens the ability to provide adequate care.
Furthermore, studies have shown that extending the duration of antibiotic therapy
from the typical 2-4 weeks does not provide any additional benefits and is
associated with adverse side effects that include diarrhea and sepsis, leading to
hospitalization in some cases [104–106].
There is currently no known explanation for the underlying mechanisms of
post-treatment Lyme disease syndrome, though the cause of PTLDS may be
multifactorial. There are a number of hypotheses that attempt to explain the ongoing symptoms: persistent B. burgdorferi infection at undetectable levels,
autoimmune mechanisms, the Amber hypothesis, or epigenetic manipulation
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within the host as outlined in this work [107,108]. The Amber hypothesis initially
sought to describe the pathogenesis of Lyme arthritis that is caused by nonviable B. burgdorferi or bacterial debris in regions that are more difficult to clear
by resident immune cells [108]. This has been extrapolated to include the CNS,
and studies have shown that heat-inactivated or sonicated Borrelia induces an
inflammatory response in microglia [109]. The work described herein provides an
additional explanation for PTLDS, focusing on epigenetic manipulation of host
cells in response to B. burgdorferi that creates a transcriptome profile that is
conducive to a pro-inflammatory state.
The Host Transcriptional Response to
Borrelia burgdorferi Sensu Lato
With the advent of next-generation sequencing technologies, the ability to
perform transcriptome analysis has become much more accessible and
affordable. The past several years have seen a dramatic increase in RNA-seq
analysis that allows researchers to conduct genome-wide transcriptome profiling
of both model and non-model organisms. The impact of this technological
innovation is best seen in studies of host-pathogen interactions. The use of RNAseq and microarray technologies aids in understanding the development of the
host response to a disease. This can better illustrate the host immune response
towards a pathogen and how the pathogen may overcome these obstacles.
Particularly, regarding B. burgdorferi, the host immune response and subsequent
inflammation, while generally beneficial, poses a deleterious outcome for patients
with Lyme disease, especially if such symptoms are persistent. With such a
tremendous evolution in sequencing technologies, researchers are able to better
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understand this dichotomy in Lyme disease. Furthermore, bioinformatics
provides the tools necessary to analyze the large amounts of data available in
such experiments. This allows researchers to not only perform transcriptome
profiling but to determine functional and pathway analysis to quantitatively
identify key targets for future therapeutics. As the goal of my projects revolved
around understanding the genetic and epigenetic alterations following B.
burgdorferi infection, this section highlights many of the past and current studies
that have utilized RNA-seq and microarray technologies in Lyme disease models
to understand the host transcriptome response.
Transcriptional Response of Early Localized Infection
Lyme disease begins at the site of the tick bite where B. burgdorferi and
tick saliva are transmitted to the host during feeding [110]. Though many studies
cited throughout this review do not utilize ticks as a route of transmission, it is
important to note the role of tick saliva in Lyme disease. Tick saliva contains a
milieu of immunomodulatory factors that include antihistamines, antioxidants, and
anti-complement proteins that promote bacterial survival [111–113]. The saliva
has been shown to inhibit neutrophil functions and impedes the killing and
clearing of bacteria; the proteins ISL 929 and ISL 1373 have been shown to
inhibit neutrophil chemotaxis to the site of infection [114,115]. Furthermore,
dendritic cell (DC) migration and maturation are also inhibited by tick saliva,
specifically Prostaglandin E2 [116,117]. These anti-inflammatory and
immunosuppressive effects aid in the initial establishment of a localized infection
at the skin of the host. This section summarizes the transcriptional alterations
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within tissue and cells that first encounter B. burgdorferi during the early phase of
the disease.
Dendritic cells.
Dendritic cells (DCs) are phagocytic and professional antigen-presenting
cells that can be found in many tissues including the skin where they monitor for
and detect invading pathogens. As a part of the innate immune system, DCs act
as a bridge linking the innate and adaptive immune response through their ability
to activate naïve T cells following stimulation and migration to lymph nodes
[118,119]. DCs are one of the first types of immune cells to interact with Borrelia
and, upon coming into contact with DCs, are quickly engulfed, allowing for the
processing and presentation of Borrelia antigens for the activation of CD4+ T cells
[120,121]. Due to the limited number of DCs that can be collected for in vitro
investigation, it is common to derive DCs either through bone marrow or
peripheral blood monocytes (PBMCs); however, to date, only one study has
investigated the transcriptional effects between Borrelia and DCs.
Hartiala et al. utilized PBMCs from healthy donors and generated DCs in
vitro to determine the transcriptional response to Borrelia garinii (Bg), a member
of the Borrelia burgdorferi sensu lato complex [122]. Like B. burgdorferi, B. garinii
elicits a phagocytic response from DCs, in which they are processed, induce DC
maturation, and activate T cells [123]. The microarray experiments performed by
Hartiala et al. made two comparisons, Bg stimulated vs unstimulated DCs and Bg
stimulated versus LPS stimulated DCs. In both comparisons, several genes that
transcribe chemotactic cytokines were upregulated in response to Bg stimulation.
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The neutrophil chemoattractants CXCL1, CXCL7, and CXCL2, the latter also
showing chemotactic properties for polymorphonuclear leukocytes and
hematopoietic stem cells, showed increased expression compared to
unstimulated and LPS-stimulated groups, and have been previously been
implicated in the inflammatory response in later manifestations of Lyme disease
[124–127]. The gene encoding for CSF-1 was induced at greater levels in Bg
stimulated DCs; CSF-1 functions as a cytokine for hematopoietic stem cell
differentiation into macrophages, and activates macrophage phagocytosis as well
as inflammatory and chemotactic functions [128,129]. Transcripts for markers of
DC maturation and differentiation were found to be upregulated in both the LPS
and Bg stimulated groups – ADAM19, CD83, and SLAMF1 [130–133]. Further
evidence of the DC inflammatory response to these stimuli is observed by the
induction of inflammatory cytokine genes – TNF-α, IL-1α, IL-1β, and IL-6. Though
it has been previously shown that B. burgdorferi sensu lato can stimulate an
interferon response, interestingly, such a response was not seen in DCs
stimulated by Bg. Yet, interferon-inducible genes were upregulated within the
LPS group – this includes IFIT1, IRF2, and IRF7. One of the principal findings by
Hartiala et al. was the demonstration of a reduced response in CD38 and CCR7
expression in DCs stimulated by Bg when compared to LPS. During
differentiation to immature DCs, CD38 is downregulated, but expressed following
DC maturation and is required for DC chemotaxis and transendothelial migration
[134,135]. Similarly, CCR7, a chemokine receptor, is a key promoter for DC
migration to the lymph nodes [136]. This results in an impaired and weakened
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humoral response and is posited by the authors as a possible cause for the
immune abnormalities associated with Lyme disease [122]. This is in line with
similar experiments that utilize ex vivo skin models injected with B. burgdorferi
sensu stricto, LPS, or Pam3CSK4 (TLR2 agonist) to measure dendritic cell
activation and migration [137]. Here, the authors observe the TLR2-mediated
migration of DCs in response to B. burgdorferi, however, the expression of CCR7
and CD38 were comparable to PBS controls, while LPS and Pam3CSK4 induced
significant upregulation of these markers. Infection of monocyte-derived DCs with
B. burgdorferi, again, did not show an upregulation of CCR7 and CD38[137].
Macrophages.
A second prominent immune cell found in the skin are macrophages.
Historically, macrophages and dendritic cells have been considered distinct cell
types based on morphology, phenotypic characteristics, and function; however,
current understanding has shown that both cell types, while unique in some
respects, share many of the same functional characteristics. Like DCs,
macrophages play a central role in the innate immune response during pathogen
invasion. While both are antigen-presenting, macrophages are predominantly
phagocytic, clearing cellular debris and pathogens while modulating an
inflammatory response through the secretion of cytokines to alert the adaptive
immune system [138,139].
To study the innate immune response to B. burgdorferi, CarrerasGonzález et al. utilized RNA-seq, among other techniques, to investigate the
transcriptional profile of primary murine bone marrow-derived macrophages
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(BMMs) following infection. Following stimulation, a large number of differentially
expressed genes (DEGs) were observed (2,066 upregulated and 2,315
downregulated), with gene expression consistent with an innate immune and
inflammatory response. The pattern of gene transcription involved biological
processes for the recruitment, differentiation, and activation of leukocytes. A
sizable number of DEGs (317) that were regulated by B. burgdoferi were directly
related to the inflammatory response, and 64 DEGs were found to be involved in
phagocytosis, a significant function of macrophages. Transcriptional fingerprint
analysis identifies expression profiles of signaling pathways to be compared with
the observed profile. Unsurprisingly, the macrophage expression profile following
exposure to B. burgdorferi resembled the fingerprint for the recognition of
bacteria and viruses by pattern recognition receptors (PRRs); more specifically,
pathway mediators within toll-like receptor (TLR) signaling showed a significant
increase in stimulated BMMs. TLRs are a well-recognized and studied receptor
family required for the innate immune response that is activated during Borrelia
infection, and TLR2 signaling has been extensively shown to be a predominant
pathway in the induction of a pro-inflammatory response [140–142]. Nonetheless,
due to the numerous TLRs and their ability to form heterodimers such as TLR1/2
and TLR2/6, studies have shown that such an immune response to B. burgdorferi
is not restricted to only TLR2. TLR2-deficient mice show poor response to B.
burgdorferi which allowed the bacteria to persist at elevated levels for at least 8
weeks [143]. Furthermore, in the same investigation, though macrophages from
TLR2-/- mice showed no response to OspA, an outer surface protein known to
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signal through TLR2, sonicated spirochetes did stimulate a macrophage
response [143,144]. Additionally, another study showed that in TLR2 knock-out
mice, macrophages were still able to activate and respond to spirochete lysates
[142]. However, the role of TLRs is diminished in the current study by CarrerasGonzález and colleagues. Though there was a significant overlap in the number
of genes between stimulated BMMs and TLR2 or PAM3CSK4 (a TLR2 agonist)
signaling pathways, the percentage of shared genes was less than 10% suggesting that a greater diversity in signaling receptors are responsible for the
overall response, as seen with an upregulation in receptor Nod2 and overlap with
triggering receptor expressed on myeloid cells-1 (TREM-1) receptor signaling.
TREM-1 is a receptor that amplifies a pro-inflammatory response, and while a
more robust inflammatory response could provide efficient clearing of an invading
pathogen, it can lead to substantial cell death and tissue damage – a concept not
unfamiliar to the Lyme disease field [80,145–148]. However, in a study using
TREM1-/- mice infected with Leishmania major, Legionella pneumophila, or
influenza virus, the mice displayed a significant attenuation of disease pathology
in regards to inflammatory infiltrates and a reduction in the expression of proinflammatory cytokines, yet were equally capable of clearing the infection
compared to controls [149]. In fact, additional studies of B. burgdorferi infection
implicate the TREM1 pathway as a significant contributor to the pathogeninduced inflammatory response [150,151]. The inflammatory response by BMMs
was further highlighted by the reduction in signaling intermediates induced by
peroxisome proliferator-activated receptor (PPAR), an inflammatory suppressor,
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and the downregulation of Il10ra, the receptor for the anti-inflammatory
interleukin-10. Furthermore, several pro-inflammatory cytokines were shown to
be upregulated including IL-1β, IL-6, IFNβ1, and TNF (a regulator of TREM1).
Overall, the study showed an inflammatory response by BMMs following B.
burgdorferi infection that was characterized by an increase in pro-inflammatory
cytokines, a reduction in anti-inflammatory pathways, and an increase in
phagocytic related genes.
Monocytes.
In addition to transcriptional profiling of murine macrophages, CarrerasGonzález et al. further characterized the transcriptional response of the
interaction between B. burgdorferi and human CD14+ peripheral blood monocytes
via microarray analysis to determine their relevance in the human innate immune
response. A similar number of DEGs were found in the human monocytes
compared to BMMs. A significantly reduced number of DEGs were shared
between the two cell types, most likely attributed to differences across species –
195 DEGs upregulated and 161 DEGs downregulated in both groups; 168 genes
were regulated in opposite directions. However, similarities appeared following
functional and pathway analysis in which pathways involving the recruitment of
leukocytes, phagocytosis, and endocytosis were increased. Furthermore,
analysis regarding upstream regulators indicated similar patterns of gene
expression for receptors TLR3, TLR9, TLR, and NOD2, and proinflammatory
cytokines TNF, IL-1α, IL-1β, and IFNα2. The gene expression pattern for the
inhibition of the anti-inflammatory IL10RA pathway was observed in both BMMs
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and human monocytes. While there were distinct differences between the two
groups regarding expression of specific genes, it appears that infection with
B. burgdorferi produces a pro-inflammatory response that overlaps both groups.
Dermal fibroblasts.
The skin represents an important obstacle in the progression of Lyme
disease as it forms a complex physical barrier comprised of the epidermis,
dermis, and hypodermis. B. burgdorferi establishes a local infection within the
dermis, and aside from resident immune cells such as DCs and macrophages,
dermal fibroblasts are among the first cells to come into contact with the
spirochetes [152–154]. Fibroblasts are the main resident cells in the dermis and
play an important role in the formation and reorganization of the extracellular
matrix (ECM). Moreover, fibroblasts are able to communicate and modulate local
immunocompetent cells as a functional part of the innate immune response
through the recruitment of leukocytes, inflammatory regulation, and the
maturation of dendritic cells [155,156].
To understand the role of dermal fibroblasts in skin inflammation during
the early pathogenesis of Lyme disease, Schramm et al. performed microarray
analysis of human dermal fibroblasts in response to three different strains of
Borrelia burgdorferi sensu stricto [154]. The three strains of B. burdorferi were
isolated from different environments representative of different stages of Lyme
disease – strain N40 was isolated from a tick, strain Pbre from an erythema
migrans skin biopsy, and strain 1408 from a skin biopsy of acrodermatitis
chronica atrophicans (ACA), a late-stage manifestation of Lyme disease. Across
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all three infection groups, a total of 241 genes were found to be differentially
expressed, with 103 genes upregulated and 138 downregulated. There were
47 upregulated and 28 downregulated DEGs that were shared between all three
groups. The authors state that there were no discernable differences in relevant
transcriptional pathways across each group and note that while the three
B. burgdorferi isolates stem from different environments of the pathogen life
cycle, the dermal fibroblasts produced similar transcriptional profiles in response
to each pathogen isolate. As one of the major functions of fibroblasts, ECM
production and remodeling genes were found to be upregulated among the
shared genes. These involve the structural components that include integrin
ITGA1, laminin LAMA1, microfibrils MFAP3, and collagen fibrils COL8A1. Most
importantly, three matrix metalloproteinases (MMPs) were found to be
upregulated – MMP-1, MMP-3, and MMP-12. The induction of MMPs by the
bacteria has been linked to the development of Lyme arthritis showing similar
erosive and inflammatory pathologies to rheumatoid arthritis [157–159]. MMP-1
and MMP-3 have been shown to be elevated in the synovial fluid of Lyme arthritis
patients [159,160]. B. burgdorferi appears to induce the production of host MMPs
to degrade and digest extracellular matrix proteins that allow for greater
dissemination [161,162].
In addition to the upregulation of ECM remodeling pathways, the
transcriptional response in fibroblasts was largely indicative of a pro-inflammatory
profile. A high level of cytokines and chemokines were shown to be upregulated,
including CXCL1 and many interleukins. Additionally, many upregulated genes
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were representative of signaling mediators that regulate and sustain an
inflammatory response such as NF-κB transcription factors (NF-κB1, -2),
interferon-related and inducible genes (IRF1, STAT1/2, OAS2, and IFIH1), and
genes within the tumor necrosis factor family (TNFSF10, TNFSF13B). Through
the release of secreted factors, dermal fibroblasts appear to communicate with
innate immune cells that allow for their attraction, activation, and maturation to
the site of infection [163–167]. Moreover, during the localized infection phase,
dermal fibroblasts inadvertently provide a means for B. burgdorferi dissemination
by the induction of ECM degradation factors like MMPs [154].
Transcriptional Response of Early Disseminated Infection
The next phase, following the initial localized infection of Lyme disease, is
the early dissemination of B. burgdorferi to other host tissue and organs.
Hematogenous dissemination is the primary mechanism for the spread of the
spirochete in the host and the first barrier that the spirochetes interact with is the
endothelial barrier of the blood vessels. This is also a primary barrier that must
be overcome by innate and adaptive immune cells.
Endothelial/Epithelial.
Dame et al. sought to determine the role of endothelial cells in Lyme
disease by performing microarray analysis of a human umbilical vein endothelial
cell (HUVEC) in vitro system infected with B. burgdorferi [168]. T lymphocytes
have long been implicated in the pathogenesis of Lyme disease and specifically
Th1 cells have been shown to be elevated in the synovial fluids of Lyme arthritis
patients [169,170]. Furthermore, Th1 cells which specifically secrete IFN-γ have
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shown a migratory affinity towards endothelia that have been stimulated by
B. burgdorferi, and a significant correlation has been shown between symptom
score of LD patients and IFN-γ [169,171]. To this end, Dame and colleagues
further sought to identify the synergistic effects of IFN-γ and B. burgdorferi on the
transcriptional profile of primary human endothelial cells.
In the presence of B. burgdorferi, HUVECs showed poor activation and
minimal differential gene expression, in which no genes were significantly
downregulated, and only 23 genes were significantly identified as upregulated
with a greater than 2-fold change. Of these genes, several have already been
identified to be induced by B. burgdorferi in a number of in vitro and in vivo
models – these genes include immune cell adhesion molecules (ICAM-1, VCAM1) and leukocyte recruitment chemokines (CXCL8, CCL2), which have been
specifically shown to promote the transmigration of leukocytes across endothelia
during B. burgdorferi infection [171–175]. Stimulation of HUVECs with IFN-γ only
produced a larger transcriptional change in both magnitude and number of genes
when compared to B. burgdorferi only, with a subset of genes being classified as
mediators of inflammation. However, the combinatorial effects of IFN-γ and
infection revealed several inflammatory and immune-related genes that were
significantly upregulated and showed a robust fold change compared to each
individual treatment. The authors formulated a synergistic scoring system that
indicated 34 genes that were differentially upregulated in both individual
treatments. This effect can be clearly seen in the expression of CCL8: IFN-γ only
treatment – 17.672 FC; Bb only treatment – 1.31 FC; and Bb+ IFN-γ treatment –
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113.58 FC. Of these 34 genes that were markedly upregulated, 9 are involved in
the recruitment of leukocytes which include specifically T lymphocyte
chemoattractants CCL7, CCL8, CXCL9, CXCL10, CXCL11, CX3CL1 and also
the aforementioned adhesion molecules (ICAM-1, VCAM-1), as well as the
neutrophil chemoattractant CXCL2 [124,176–180]. Furthermore, the presence of
T lymphocytes has been attributed to more persistent inflammatory syndromes
[181–184]. Many of the 34 genes are mediators in both the innate and adaptive
immune systems; however, interestingly, the CIITA gene showed downregulation
in Bb only treatment, but an upregulation in IFN-γ only, and an even greater
upregulation with the combination of treatments. CIITA encodes for the MHC
class II transactivator and acts as a master regulator for MHC class II genes,
involved in antigen processing and presentation. This change in gene expression
brought upon by IFN-γ treatment is suggestive of a transition towards the
adaptive immune response. Together, the transcriptional changes observed
indicate a key role of endothelial cells in conjunction with IFN-γ that leads to a
greater adaptive immunological response through the selective recruitment of
T lymphocytes, and as Th1 cells themselves produce and secrete IFN-γ, a
positive-feedback loop would promote a more chronic inflammatory environment
which is seen in Lyme disease patients [168–170,185–187].
Peripheral blood mononuclear cells.
During hematogenous dissemination, B. burgdorferi encounters a wide
variety of immunocompetent cells within the blood circulatory system. Due to the
ease of access, availability, and as one of the predominate classes of immune
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cells in the blood, peripheral blood mononuclear cells (PBMCs) are commonly
used in both ex vivo and in vivo analysis of Lyme disease. PBMCs are defined as
any peripheral blood cell that has a round nucleus, as opposed to anucleur cells
such as mature erythrocytes or multi-lobed nucleated cells such as granulocytes.
They are predominately comprised of lymphocytes (T cells, B cells, and NK cells)
and to a lesser extent monocytes [188,189].
To determine the global and temporal transcriptional pathways involved
during B. burgdorferi infection in humans, Bouquet et al. performed longitudinal
transcriptome analysis (RNA-seq) of PBMCs collected from patients with acute
Lyme disease at three time points: time of diagnosis/pre-treatment, treatment
completion (3 weeks), and 6 months post-treatment to determine the
transcriptional profiles of post-treatment symptoms. 29 individuals with acute
Lyme disease that presented with a documented EM rash and flu-like symptoms,
such as fever, fatigue, and the onset of muscle or joint pains, were enrolled in
addition to 13 healthy control individuals. Following 6 months post-treatment, the
29 individuals were further categorized as having resolved the illness (n=15) or
experiencing persistent symptoms (n=13); one patient was lost to follow-up. Of
the 13 with persistent symptoms, 4 were diagnosed with post-treatment Lyme
disease syndrome. The authors also note that the longer the duration between
the onset of symptoms and the time of completed treatment was correlated to
PTLDS diagnosis, in which non-PTLDS patients had an average duration of
9.7 days between symptom onset and treatment completion and 19.3 days for
PTLDS patients.
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Transcriptional analysis showed a consistent decrease in the number of
DEGs across the three time points compared to controls – pre-treatment:
1235 DEGS, treatment completion: 1060 DEGs, 6-months post-treatment: 686.
Interestingly, when taking into consideration other infectious diseases such as
Influenza, the gene expression of patients with Lyme disease failed to return to
baseline levels; however, persistent symptoms were not solely dependent on this
failure to return to baseline as no DEGs were found between patients with
resolved symptoms and those with persistent symptoms. Pathway analysis of the
pre-treatment group indicated activation of the inflammatory response, immune
cell trafficking, hematological system, as would be expected during the early
dissemination phase of B. burgdorferi. However, these pathways remained
activated at treatment completion and to a lesser extent at the 6-month posttreatment time point. This is reflected in the top 10 enriched pathways in that
8 pathways of the pre-treatment, 10 pathways in treatment completion group,
and 4 pathways in 6-month post-treatment group were directly related to the
immune response. Furthermore, TREM-1 signaling was the top activated
pathway for both pre- and completed treatment groups. As mentioned previously,
TREM-1 acts as an amplifier of inflammation, and also acts as a mediator for Th1
activation through factors such as DAP12, IL-6, IL-12 that were upregulated in
these two groups. Inversely, the eIF2 signaling pathway was found to be
downregulated in all three groups and has been found to be involved in protein
synthesis during cellular stress [190]. The pathogen Legionella pneumophila was
previously shown to disrupt and downregulate mediators of this pathway through
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the secretion of effectors, and defective signaling of eIF2 was shown to lead to
greater susceptibility to intracellular invasion by Yersinia pseudotuberculosis,
Listeria monocytogenes, and Chlamydia trachomatis [191,192]. However, the
current mechanism and immunological impact of eIF2 signaling inhibition
following B. burgdorferi infection is yet to be elucidated. Several TLRs were also
found to be either upregulated or predicted to be activated that include TLR-1, -2,
-4, -7, and -8. Additionally, within the first two groups, the majority of upstream
regulators were proinflammatory cytokines such as CSF2, IFN-γ, TNF-α
(a master regulator of eIF2, TREM1, and TLR signaling), anti-inflammatory
cytokines IL-6 and IL-110, and the transcription factor NF-κB. In contrast, the top
upstream regulators for the 6-month group mainly involved genes associated
with the regulation of gene expression such as MYCN, MYC, and FOS. Overall,
Bouquet et al. found that the transcriptional profile of acute Lyme disease
patients prior to treatment and upon treatment completion shared many
characteristics, with many overlapping DEGs involved in the inflammatory and
immune process but the activation of inflammatory T-cell apoptosis and B-cell
developmental pathways were inhibited when compared to other acute infectious
diseases. While the 6-month post-treatment group did not produce a marked
inflammatory response, it failed to return to baseline levels; however, when
compared to the transcriptional profiles of other immune-mediated chronic
diseases such as systemic lupus erythematosus, up to 60% of the pathways
overlapped.
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Transcriptional Response of Late Disseminated Infection
Joint (mouse).
The late disseminated phase of Lyme disease is characterized by
successful invasion of secondary tissue and organs, including joints, heart, and
CNS, followed by subsequent clinical presentations associated with affected
tissue. A common outcome of dissemination into the joints is Lyme arthritis, in
which 30% of patients will develop it and up to 60% if treatment was not
administered at the time of infection [66,67,193]. The laboratory mice have long
been used as a model for Lyme arthritis, and as such, Crandall et al. used two
strains of mice that developed either severe arthritis (C3H) or mild disease
(C57BL/6), as well as C578BL/6-IL-10-/- that lacked the anti-inflammatory
cytokine IL-10, to study the global gene expression within the joints of these
animals in response to B. burgdorferi [194–196].
Expression profiles of rear ankle joints were determined by microarray
analysis at 1, 2, and 4 weeks of infection. At week 1, C3H, C57BL/6, and
C578BL/6-IL-10-/- had an increase in 156 genes, 119 genes, and 419 genes,
respectively. Interestingly, only 3 genes overlapped between C3H and C57BL/6.
At week 2, significant inflammatory response and immune cell infiltration were
evident through gene expression and histological analysis in all three strains; 302
DEGs were shared among the three groups. In agreement with histological
evidence of leukocyte recruitment, an increase in the expression of recruiting
chemokines was observed: PMN-recruiting (CXCL1, CXCL2, CXCL5),
mononuclear cell-recruiting (CCL2, CCL3, CCL7, CCL12), and T cell-recruiting
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(CXCL9, CXCL16, CCL2, CCL7). Transcripts for antigen-presenting cells and
antigen processing such as MHC, CD1, and TAP1/2 were elevated at 2 and
4 weeks; this is suggestive of an active adaptive immune response.
B. burgdorferi is known to activate the production of several pro-inflammatory
cytokines such as TNF-α, IL-1β, or IFN-γ, many of which are mediated by the
activation of NF-κB. However, in C3H and C57BL/6 mice, only IL-1β was found to
be increased in the joints. This is suggestive that these cytokines fail to be
induced by B. burgdorferi in the presence of the anti-inflammatory cytokine IL-10,
as the production of many of these inflammatory cytokines were robustly induced
in IL-10-/- mice, including IL-1β, IFN-γ, IL-15, and members of the TNF family.
Due to this response in IL-10-/-, these mice were able to more effectively control
bacterial growth but at the cost of developing more severe arthritis. Though
induction of Type I and II IFN was not detectable in C3H, a robust IFN induced
response was displayed – the IFN induced GTPases, Igtp, Iigp2, and Iigp1 saw a
fold-change of 128, 123, and 113 respectively when compared to control at week
1. Additional IFN related genes include IFI1, GBP2, OASl2, and signaling
molecules Stat1, IRF1, IRF2, IRF7, and IRF8. In the study, the authors note that
the cause of IFN-related transcription cannot be determined as the presence of
Type I/II IFNs were not detectable in either C3H and C57BL/6. However, more
recent studies shed light on this phenomenon that indicate receptors
independent of IFN receptors may be responsible, such as TLRs [197]. However,
in stark contrast of this, C57BL/6 mice did display any increase of these IFNinducible genes at week 1, and only minimal expression at week 2, which
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corresponded to less severe arthritis. This association with arthritis and gene
expression in further observed in IL-10-/ mice that saw a robust IFN-induced
response that significantly increased according to a longer time point.
Furthermore, C57BL/6 mice saw an increase in transcripts related to epidermal
differentiation and wound repair, compared to either no change or
downregulation of these same genes in the other two strains across all time
points. The study performed by Crandall et al., provides transcriptional insight of
late dissemination associated with Lyme arthritis, showing a robust inflammatory
response corresponding to disease severity, and upregulation of epidermal and
wound repair genes correlating to a more protective effect [194].
Astrocytes.
Neuroborreliosis is defined by the invasion of the CNS by B. burgdorferi
sensu lato, leading to subsequent neurological manifestations. Due to the
disease severity and difficulty in treatment of persistent symptoms, many studies
have been aimed to understand the mechanisms that lead to this pathology.
Another study performed in the Brissette laboratory, Casselli et al., investigated
the role of astrocytes in the exacerbation of neuroborreliosis through the use of
RNA-seq [198]. Astrocytes, a resident glial cell, are the most abundant cell in the
brain and play a role in a wide variety of functions [199]. Their functions include
nutrient support, neurotransmitter recycling, aiding in synaptic remodeling and
plasticity, structural support which includes the formation of the blood-brain
barrier, and responding to CNS injury and infection through inflammatory and
immune modulation [199,200].
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Casselli et al. used primary human astrocytes in vitro stimulated by Bb for
24 and 48 hours. 275 transcripts were found to be differentially expressed at both
time points with significant overlap between them (221 DEGs). Tumor necrosis
factor superfamily, member 18 (TNFSF18) showed the strongest induction with a
fold-change of 440 and 580 for 24 hours and 48 hours, respectively. Additional
inflammatory and immune-related genes were upregulated that include
chemokines CXCL1, CXCL6, and CXCL8 as well as ERAP2 which is involved in
innate immunity and antigen processing and presentation [201]. In line with the
broad nature of astrocyte functionality, biological and functional analysis
indicated genes were involved in nervous system development, angiogenesis,
and cell adhesion. While these experiments indicated an inflammatory and
immune response following B. burgdorferi infection, it seems the response was
less concerted compared to more specialized peripheral immune cells. This may
suggest and provide credibility to disease severity that correlates to the invasion
of peripheral immune cells into the CNS, as seen in the CSF of neuroborreliosis
patients. Such an outcome may lead to a dysregulation in astrocytic function and
result in exacerbation of a more persistent inflammatory environment within the
CNS.
Gap in Knowledge
The work presented herein aims to elucidate the mechanisms underlying
two major questions surrounding the neurological manifestations of Lyme
disease. They are 1) How does B. burgdorferi enter the central nervous system,
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and 2) How does B. burgdorferi induce persistent neurological symptoms present
in PTLDS patients.
Regarding the first question, it is quite evident that B. burgdorferi is able to
enter the central nervous system, however, where and how this occurs is still a
matter of debate. The CNS is a highly regulated system that is selectively
permeable through its barriers such as the blood-brain barrier and the blood-CSF
barrier. In order to understand the pathogenesis of Lyme disease and how the
dissemination into the CNS leads to the clinical presentations of neuroborreliosis,
it is important to understand the mechanisms of entry. The choroid plexus forms
the blood-CSF barrier, and due to its anatomical position and functions, it is a
structure that we have chosen to investigate. The choroid plexus is situated
within the ventricles of the brain, with the epithelial cells forming the blood-CSF
barrier through tight and adherens junctions, and it is the predominate producer
of CSF. Previous studies have shown its predisposition in the transmigration of
peripheral immune cells and possibly pathogens into the CSF. It is applicable to
note that a defining characteristic of neuroborreliosis is lymphocytic pleocytosis,
an abnormal elevation of lymphocytes in the CSF, and B. burgdorferi or its DNA
is found in the CSF of patients. The next chapter discusses the relevance of the
choroid plexus’ function, its role in the context of other infectious diseases, and
the results of our experiments investigating the impact of B. burgdorferi on
primary human choroid plexus epithelial cells in vivo.
Regarding the second question, the history of post-treatment Lyme
disease syndrome has been plagued by controversy and is frequently and
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incorrectly referred to as “chronic Lyme disease”, a term since rejected by the
scientific community [99,202–204]. Much of the confusion is due to a lack of
evidence for a conclusive cause of PTLDS. The Amber hypothesis suggests that
the debris of dead B. burgdorferi continues to elicit an inflammatory response,
and due to the disseminating nature of the bacteria, the debris may be located in
difficult to clear regions of the body, such as the extracellular matrix of joints or
the CNS [108]. However, as presented in Chapters 3 and 4, we hypothesized a
new approach, that is not necessarily mutually exclusive to prevailing lines of
thought. Our central hypothesis states that during active infection and
subsequent inflammatory host response, B. burgdorferi induces long-term
epigenetic modifications in host cells that are conducive to a persistent
inflammatory state. This hypothesis is extended to our current interests, focusing
on the central nervous system and more specifically to a resident glial cell,
astrocytes. Two epigenetic alterations, namely DNA methylation and chromatin
accessibility, are explored in chapters 3 and 4, respectively.
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Introduction
The choroid plexus (CP) is a complex that has been implicated in the
trafficking of immune cells across the blood-CSF-barrier (BCSFB). In addition to
its role in the formation of the BCSFB, it is the major producer of CSF [205,206].
The CP is a highly vascularized structure within the ventricles of the brain, and
unlike the blood-brain barrier (BBB), the capillaries within the choroid plexus are
highly fenestrated. Instead, the choroid epithelial layer is responsible for the
selective permeability of the BCSFB through the formation of tight and adherens
junctions at the apical lateral surfaces [207]. An interesting characteristic of the
choroid plexus is the presence of immune cells on the basolateral side within the
stromal matrix – this includes dendritic cells and macrophages (Figure II-1) [208–
211]. A further illustration of the immune-surveillance role of the choroid plexus is
shown in the presence of cell adhesion molecules on CP epithelium and not the
neighboring endothelium, which mediate the binding of immune cells [212]. The
transmigration of macrophages and peripheral blood mononuclear cells (PBMCs)
across the choroid plexus epithelium was observed in transwell and explant
cultures in the presence of feline immunodeficiency virus [213]. In a human
barrier model of the choroid plexus, the transepithelial migration of
polymorphonuclear neutrophils and monocytes was observed following bacterial
infection (Neisseria meningitidis) [213]. It is understood that the context of a
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Figure II - 1.

Structural features of the choroid plexus.
Under healthy conditions, the choroid plexus maintains
peripheral immune cells within the stromal matrix as a form of
immunosurveillance. Multiple receptors are present on the
epithelium, including cytokine and pattern recognition receptors.
The BCSFB is formed by the epithelium through tight junctions,
adherens junctions, and desmosomes. During infection or
disease states, these junctions may be altered, immune cells
may transmigrate across the epithelium, and cytokines from both
the epithelial cells and activated immune cells are released.
Many of these cytokines induce a pro-inflammatory response
and act as chemoattractants for innate and adaptive immune
cells. Created with Biorender.com.
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bacterial infection and the inflammatory profile of the CSF determines the
severity and overall outcome of patients [214–216]; therefore, due to the choroid
plexus’s anatomical position in separating the periphery and CNS, as well as its
secretory, barrier, and immune response roles, the intent of this project was to
investigate the effects of Borrelia burgdorferi infection on choroid plexus epithelial
cells.
The overall aim of this study is to determine the transcriptome profile of
primary human choroid plexus epithelial cells (HCPECs) during B. burgdorferi
infection. Using HCPECs in culture, we demonstrated differential expression of
258 genes following infection with B. burgdorferi after 48 hours. Functional and
pathway analysis of these transcriptional changes revealed upregulation of host
inflammatory and immune responses, related to interferon, chemokine, and
cytokine pathways, as well as immune cell trafficking and activation. Although
this model does not provide a barrier context, interestingly, functional and cellular
components involving cell-cell junctions and tight junctions were seen to be
downregulated. Here we present our findings of differential gene expression in
HCPECs following infection with B. burgdorferi.
Methods
Bacteria Culture
The Borrelia burgdorferi strain B31-MI-16 is an infectious clone which was
previously sequenced and described [20,217]. Bacteria cultures were grown to
approximately 1 x 107 bacteria/ml in modified Barbour-Stoenner-Kelly (BSK-II)
medium supplemented with 6% rabbit serum at 34°C and used at passage 2.
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Cell Culture
HCPECs were obtained from ScienCell Research Laboratories (Carlsbad,
CA; catalog #1310). Commercially available human primary cell cultures and
protocols used throughout this study followed the University of North Dakota IRB
guidelines outlined in form 504 “Categories of Research”, section 2.19
“Commercially Available Human Biological Specimens (45 CFR 46.102, 46.103,
and 46.116)” and therefore do not require IRB review. The purity of cells was
assessed and confirmed by immunofluorescence, the following primary
antibodies and concentrations were used: Rabbit anti-Prealbumin (TTR)
conjugated to Alexa Fluor 488 (Abcam, catalog #ab199074; Conc. 1:50), Mouse
anti-α-Tubulin (Sigma, catalog #T61999; Conc. 2 ug/ml), Mouse anti-CK18
(Abcam, catalog #ab82254; Conc. 1:50). The secondary antibody, Donkey antiMouse conjugated to Alexa Fluor 594 (Jackson Immunoresearch, catalog #715585-151, Conc. 1:100), was used for anti-CK18 and anti-α-Tubulin antibodies.
For immunofluorescence, cells were grown on glass coverslips and fixed with a
4% paraformaldehyde solution for 15 minutes and stored in PBS at 4°C.
Permeabilization was performed with a 0.1% Triton-PBS solution for 10 minutes
and blocked with a 10% Donkey (Jackson immunoresearch, catalog #017-000121) or Goat Serum (Jackson Immunoresearch, catalog #005-000-121) in 0.1%
Tween-PBS solution for 1 hour. Primary antibodies were incubated overnight at
4°C. Secondary antibodies were incubated for 1 hour at room temperature. DAPI
Fluoromount-G (SouthernBiotech, catalog #0100-20) was used for nuclei
staining. Western blot analysis was performed on control and infected cell lysates
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to determine the presence of TTR and CK18 – previously mentioned primary
antibodies were used in conjunction with the secondary antibodies: Donkey antirabbit conjugated to peroxidase (Jackson Immunoresearch, catalog #711-035152, Conc. 1:200,000) and Goat anti-mouse conjugated to peroxidase (Jackson
Immunoresearch, catalog #115-035-003, Conc. 1:200,000). Signal was produced
by SuperSignal West Femto Maximum Sensitivity Substrate kit from
ThermoFisher Scientific (catalog #34094) and imaged on a Licor Odyssey Fc
Imaging System.
Cells were maintained in tissue-treated vented cap T-75 flasks (Corning,
catalog #430641U) in epithelial cell medium (ScienCell, catalog #4101),
containing antibiotics penicillin (100 units/ml) and streptomycin (100 ug/ml)
(ScienCell, catalog #0503), 2% fetal bovine serum (ScienCell, catalog #0010),
and EpiCGS (ScienCell, catalog #4125). Two groups were used for these
experiments – Control, non-infected (n=3) and Infected, 48 hours (n=3); a total of
6 samples. Cells were incubated at 37°C and used at passage 3 at
approximately 80% confluence for stimulation by Bb. Prior to infection, the cell
cultures were washed 3 times with sterile Dulbecco’s phosphate buffered saline
(DPBS) and the medium replaced with antibiotic-free epithelial cell medium. Cell
cultures were stimulated with B. burgdorferi at a multiplicity of infection (MOI) of
10:1 (bacteria:cells) for 48 hours. Mean cell count of HCPECs was determined
using an automated cell counter (Life Countess II, catalog #AMQAX1000) to
determine an appropriate number of bacteria for infection. Control non-treated
flasks were prepared identically without infection. Light microscopy was used to
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monitor cell morphology and confluency. Additionally, cell proliferation was
monitored using an MTS assay (Abcam, catalog #ab197010) and colorimetric
plate reader in a 96-well plate under identical conditions. Apoptosis and necrosis
were determined by fluorescence microscopy using Apopxin Green Indicator
(Apoptosis) and 7-AAD (Necrosis) on cells grown in 24-well plates on glass
coverslips under identical conditions (Abcam, catalog #ab176749) and manually
counted.
RNA Isolation
RNA was isolated via phenol-chloroform extraction and using the RNeasy
Mini kit from Qiagen (catalog #74106) according to the manufacturer’s
instructions. In short, cell medium was removed from cultures and used for later
protein analysis; 1 ml of Trizol was added directly to each flask and a cell scraper
was used to fully lyse all cells. Homogenized cells were transferred to RNaseDNase free 1.5 ml Eppendorf tubes, where chloroform was added for 2 minutes
and centrifuged at 12,000 x g for 15 minutes at 4°C. The upper aqueous phase
was mixed with 70% ethanol and placed in a Qiagen RNeasy Mini column. The
flow-through was discarded and the bound RNA fraction remaining on the
column membrane was further washed and processed per Qiagen’s instructions.
Genomic DNA was removed with DNA digestion with RNase-free DNase Set
(Qiagen, catalog #79254). RNA quality was assessed with a NanoDrop and
integrity assessed by gel electrophoresis on a 2% agarose gel.
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Library Construction and RNA Sequencing
Isolated total RNA, as described above, underwent further quality control
and purification to obtain mRNA. To assess RNA integrity of total RNA, samples
were placed in an Agilent 2100 Bioanalyzer with the RNA 6000 Nano kit (catalog
#5067-1511) – all samples passed with an RNA integrity number (RIN) of ≥8.9.
To obtain a more accurate concentration, total RNA samples were run on a
broad range Qubit 2.0 Fluorometer. mRNA was enriched from total RNA samples
using the NEBNext Poly(A) mRNA Magnetic Isolation Module (catalog #E7490S)
– in short, oligo d(T) beads are used to bind the poly(A) tail of eukaryotic mRNA.
The NEBNext Ultra II RNA-seq library kit (catalog #E7775S) was used for library
construction. Libraries were checked for quality and adaptor contamination on
the bioanalyzer with the Agilent DNA 1000 kit (catalog #5067-1504). Library
concentration was assessed with a BioTek Gen5 Wellplate reader with the
Quant-iT PicoGreen dsDNA Assay kit (catalog #P11496). All samples, 3 control
and 3 infected, were then pooled and sent to Novogene
(https://en.novogene.com) for sequencing. An Illumina HiSeq 4000 was used for
150 bp paired-end sequencing.
RNA Data Analysis
Raw fastq files were received from Novogene and initial quality control
was assessed using FastQC version 0.11.2 [218]. All samples passed initial QC
following adaptor trimming using Trimmomatic [219]. Reads were aligned to the
human (hg19) assembly using Hisat2, version 2.1.0 [220] and indexed by
Samtools, version 1.9 [221]. Differential gene expression analysis was performed
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using DESeq2, version 1.24.0 [222], with an FDR of 0.05 or lower, and no fold
change cut-off. Network mapping and functional analysis was performed with
STRING database, version 11.0 [223] and verified with PANTHER, version 14.1
[224]. STRING utilizes Gene Ontology [225,226] to determine functional
enrichments within our networks.
Pathway analysis was performed using Signaling Pathway Impact
Analysis (SPIA), version 2.36.0 [227,228], which brings fold change and gene
function into context. SPIA uses the Kyoto Encyclopedia of Genes and Genomes
[229] (KEGG) database to determine impact of DEGs on the respective pathway
based on gene enrichment and topology of the pathway. Pathway enrichment is
determined from the total number of genes within a specific pathway compared
to the Number of Differential Expressed genes (NDE) observed within that
pathway; significance of pathway enrichment was set at pNDE < 0.05.
Furthermore, the topology of a pathway is taken into consideration to determine
the impact of DEGs within that pathway. The perturbations (PERT) of a pathway
caused by DEGs is determined based on the location of these genes within the
pathway; significance was set to pPERT < 0.05. Overall global significance (pG)
was determined from pNDE and pPERT. Two forms of statistical corrections pG
were performed – a Bonferroni correction (pGFWER) and a false discovery rate
(FDR) correction (pGFDR). To determine significance of a pathway, pGFDR <
0.05 was considered.
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Validation of RNA-seq Using RT-qPCR and cDNA Synthesis
Selected individual transcripts were confirmed using PCR primer sets
(Qiagen, catalog #330001). cDNA from RNA samples were synthesized using
Qiagen’s First Strand Kit (catalog #330404). Each reaction was performed
following the RT2 qPCR Primer Assay instructions – each reaction contained 1 ul
of the primer mix at 10 uM for each gene of interest, 12.5 ul RT2 SYBR Green
Mastermix, 1 ul cDNA, and 10.5 ul Nuclease-free water, for a total reaction
volume of 25 ul. qPCR was initiated with a single 10 min cycle at 95°C for initial
denaturing and activation of polymerase. Following this, 40 cycles of 15 seconds
at 95°C and 1 minute at 60°C was performed and fluorescent data was collected
at the end of each cycle. Melt curve analysis was performed at the end of the
reaction using the following conditions: 95°C, 1 min; 65°C, 2 mins; 65°C to 95°C
step-wise at 2°C/min. Expression levels of transcripts were compared and
normalized to the housekeeping gene ACTB (β-actin). Relative gene expression
between treated and untreated sample groups were compared using the 2 –ΔΔCT
method. All samples were analyzed in triplicate from three biological replicates.
Supernatant Protein Analysis by Enzyme-linked Immunosorbent Assays
Supernatants from cultures were removed as previously mentioned
following treatment. Samples were aliquoted and stored at -20°C until use.
ELISAs were performed following manufacturer’s instructions (R&D Systems,
DuoSet ELISA). Briefly, plates were coated and incubated overnight at room
temperature with 100ul of capture antibody. Following aspiration of this antibody
and washing, 100 ul of standards and sample were added to each well. Plates
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were than incubated at room temperature for 2 hours, aspirated, and then
washed. 100 ul of conjugated detection antibody was then added to each well
and incubated for 2 hours at room temperature. Colorimetric detection was
performed after the addition of a chromogenic substrate and stop solution. Plates
were read at a wavelength of 450 nm on a BioTek Epoch plate reader.
Statistical Analysis
Differential gene expression of RNA sequencing data was determined by
DESeq2. Briefly, DESeq2 utilizes an empirical Bayes approach and makes the
assumption that genes of similar transcript levels will show similar variability.
Through this, the package can control for replicate variability at each specific
gene by taking into consideration the average variability of similarly expressed
genes, and account for sample size. Furthermore, DESeq2 performs a
Benjamini-Hochberg adjustment resulting in an adjusted p-value (padj) also
called a false discovery rate (FDR). Genes with an FDR < 0.05 were considered
significant.
Statistical analysis between control and infected groups for both RT-qPCR
and ELISA was performed using an unpaired student’s t-test using GraphPad
Prism Version 8. Additional post-hoc analysis was performed on RT-qPCR to
correct for multiple t-test comparisons. The method of Benjamini, Krieger, and
Yekutieli was used to determine the FDR – this method is an updated version of
the previously mentioned Benjamini-Hochberg adjustment [230]. Transcripts for
RT-qPCR were considered significant if FDR < 0.05 (*). Protein levels from
ELISA were considered significant if p < 0.05 (*).
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Results
Prior to infection, the identity and purity of HCPECs was assessed and
confirmed through immunohistochemistry (IHC) with cytokeratin 18 (CK18), an
epithelial cell marker, and transthyretin (TTR), a marker for choroid plexus
epithelial cells and specific hepatocytes (Figure II-2A and B) – 98% of cells were
CK18 and TTR positive [231]. Figure II-2A indicates the colocalization of TTR
within CK18 labeled cells; Figure I-2B further illustrates the cytoplasmic
localization of TTR by using α-Tubulin to highlight cellular boundaries. Total
protein from control and infected groups was isolated to check for the presence
of CK18 and TTR (Figure II-2C). The effects of Bb infection on HCPEC
proliferation, apoptosis, and necrosis was measured through IHC and
colorimetric assays - no significant changes were detected between infected and
control groups.
Stimulation of Type I/II Interferon Signaling Pathway Following
B. burgdorferi Infection
B. burgdorferi infection was performed with primary human choroid plexus
epithelial cell cultures for 48 hours, and changes in the transcriptome of the
human cells were compared to untreated controls (3 biological replicates per
group). Supernatant from each replicate was collected and used for protein
analysis, and RNA was then isolated. Following RNA isolation, Illumina libraries
were made and sequenced on an Illumina HiSeq 4000 as outlined in the
Methods section. Differential gene expression analysis was performed using the
DESeq2 package in Rstudio. Following count normalization, an MA-plot
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Figure II - 2.

Characterization of primary HCPECs.
(A) HCPECs were identified by immunostaining with cytokeratin
18 (CK18 - red), an epithelial cell marker, and transthyretin (TTR
– green), a transport protein predominantly expressed by choroid
plexus epithelial cells and hepatocytes. Nuclei were stained with
DAPI (blue). Magnification: 40x, Scalebar: 40 µm. Further
observations of TTR localization within the cytoplasm of
HCPECs. (B) Colocalization of α-Tubulin (red) and TTR (green);
nuclei stained with DAPI (blue). Magnification: 60x, Scalebar:
40 µm. (C) Western blot for the presence of CK18 and TTR
(dimer). Lanes C1, C2, C3 – Uninfected HCPECs protein; Lanes
I1, I2, I3 – Protein from HCPECs infected with Bb for 48 hours.
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(Figure II-3A) was constructed – this illustrates genome-wide transcriptome
expression of the 48-hour Bb treated group when compared to the control group.
Dots in red represent significant differentially expressed genes (DEGs), plotted
as a function of its log2 fold change versus the mean of normalized counts. Using
an adjusted p-value (false discovery rate) less than or equal to 0.05, and no fold
change threshold, a total of 258 genes were shown to have significant differential
expression. A full list of these differentially expressed genes can be found in
Appendix A. Of these 258 DEGs, 160 were upregulated and 98 downregulated.
Hierarchical clustering of replicates based on treatment is further illustrated in the
heatmap analysis (Figure 2-3B) of the 258 DEGs for each replicate.
In order to validate our RNA-seq findings, RT-qPCR was performed on a
set of select genes (Figure II-4A). The upregulated genes cxcl3, cxcl6, ccl5, ifit1,
and ifitm1 were found to be significantly upregulated by RT-qPCR when
comparing 48-hour infected group to the untreated group. Although cxcl5 and irf7
transcripts were not significantly increased, an increasing trend was observed
that correlates with the RNA-seq data. Additionally, the downregulated genes
cdh2, flt1, and anxa1 showed a non-significant downward trend that corresponds
with our previous data. In order to determine if transcriptional changes observed
in response to Bb resulted in protein production and secretion from the choroid
plexus epithelial cells, we measured the cytokine levels in cell culture
supernatants by ELISA (Figure 2-4B-E). Following 48-hours post B. burgdorferi
stimulation, Cxcl1, Cxcl2, Cxcl5, and Cxcl6 supernatant concentrations were
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Figure II - 3.

RNA-seq was performed on HCPECs that were infected by
B. burgdorferi for 48 hours and from uninfected controls.
(A) MA-plot representing gene expression patterns of infected
group compared to control (n=3). Red dots indicate significant
differentially expressed genes (DEGs; FDR <0.05). A total of
258 genes were differentially expressed. (B) A heatmap of the
258 DEGs showing clustering patterns between each biological
replicate.
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Figure II - 4.

Validation of RNA-seq gene expression data.
(A) Select differentially expressed genes following 48-hour
B. burgdorferi treatment were validated by RT-qPCR. Primers
specific to cxcl3, cxcl5, cxcl6, ccl5, ifit1, ifitm1, irf7, cdh2, flt1,
anxa1, and actb were used for amplification. The relative gene
expression between 48-hour B. burgdorferi treated and untreated
control groups are expressed as Log2FC and normalized to the
housekeeping gene ACTB. Significance was calculated by
Student’s t-test (* p<0.05, n=3). (B-E) Supernatant from infected
and untreated groups were collected and analyzed by ELISA.
Concentrations of these secreted cytokines are shown as the
mean and standard deviation. Significance was calculated by
Student’s t-test followed by Benjamini, Krieger, Yekutieli
correction (* FDR < 0.05, n=3).
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assessed. Cxcl1, Cxcl2, and Cxcl5 were induced and secreted at significantly
higher levels in the infected samples compared to untreated controls. Though
Cxcl6 did not show significant elevation, a similar increase in protein levels was
observed. These data agree with our RNA-seq findings.
Both subsets of upregulated and downregulated genes were analyzed for
known interactions of their associated proteins using the STRING (Search Tool
for the Retrieval of Interacting Genes/Proteins - https://string-db.org/) database
(Figure II-5 and II-6) [223]. STRING analysis provides insight into the proteinprotein interactions of each gene – each node represents one of the DEGs; lines
between nodes correspond to known interactions that were experimentally
determined or curated from databases utilized by STRING. STRING also
provides information on functional and pathway analysis through the use of Gene
Ontology (GO) [225,226] and KEGG [229]. Upregulated DEGs (Figure 2-5A)
show two distinct clusters within the network. The first cluster, shown in the top
left, is predominantly comprised of chemokines and cytokines – the red nodes
denote genes within the chemokine-mediated signaling pathway (GO:0070098,
FDR 8.23E-08). Additionally, the second highly clustered nodes situated within
the center indicates genes associated with type I (blue) and type II (green)
interferon pathways (GO:0060337, FDR 2.71E-23; GO:0034341, FDR 9.58E-15,
respectively). The biological processes that were enriched predominantly
involved inflammatory/immune response pathways and cell-cell communication
(Figure 2-5B). A large subset of the upregulated genes was found to be
interferon pathway genes (Table II-1). Of note, the interferon-induced protein
56

Figure II - 5.

Network and functional analysis of upregulated DEGs by
STRING analysis.
(A) STRING network – Each node represents a DEG; lines
between nodes indicate known protein-protein interactions.
Nodes in blue and green correspond to type I or type II interferon
pathways, respectively; Red corresponds to chemokinemediated signaling pathway. (B) Table of select GO
enrichments.
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Figure II - 6.

Network and functional analysis of downregulated DEGs by
STRING analysis.
(A) String network – Nodes in blue and green represent cell-cell
junctions (GO:0005911) and bicellular tight junctions
(GO:0005923), respectively. Nodes in red indicate genes within
the focal adhesion pathway from KEGG pathway analysis
(hsa04510). (B) Table of selected GO enrichments.
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Table II - 1. Select inflammatory and immune response genes
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family of genes, ifit1, ifit3, ifitm1, ifitm2, ifitm3, and others, were shown to be
significantly upregulated. Type I and II interferon related genes, such as gbp2,
ifit1, and oasl, have been previously reported as being significantly elevated as a
consequence of B. burgdorferi infection [197,232]. Furthermore, major
transcription factors that were observed to be upregulated including irf7, stat1,
and stat2, have been shown to play important roles in regulating the Bb-induced
interferon response [233–235]. Interferon related genes have traditionally been
associated with viral, not bacterial, infections, and this is reflected in regard to the
labeling of gene function and pathway analysis within these data. However, it is
well documented that such genes are often observed to play key roles during
bacterial infections, including Lyme disease [236–239]. Signaling Pathway
Impact Analysis (SPIA) was performed to determine pathway enrichment based
on an increase in gene enrichment and position of genes within a pathway. A
total of 14 pathways were identified as being significantly enriched (Figure II-7).
The top activated pathways involve the activation of viral pathways, including
Influenza A, Measles, and Herpes simplex infection. As stated before, these viral
pathways involve the interferon related response as observed in our data. These
data imply that infection with B. burgdorferi produces a significant immune
response that encapsulates major interferon-signaling pathways within HCPECs.
B. burgdorferi Infection Induces a Chemokine Profile in HCPECs Conducive
to the Chemotaxis of Immune Cells
Many of the transcripts that were upregulated were categorized into proinflammatory cytokines and chemokines (Table 2-1) - these involved the C-X-C
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Figure II - 7.

Signaling Pathway Impact Analysis.
SPIA of all DEGs based on pathway gene enrichment (pNDE)
and pathway perturbations (pPERT) that take into account gene
placement and topology within the pathway. Both pNDE and
pPERT are used to determine global significance, pG. (A) SPIA
two-way evidence plot. Each dot represents a pathway that
contains at least one DEG. The impact analysis plots each
pathway based on pNDE and pPERT. Pathways above the solid
blue line are significant following FDR correction (pGFDR <
0.05). Pathways above the solid red line are significant following
Bonferroni correction (pGFWER < 0.05). (B) A table of all
significant pathways (PGFDR <0.05) and their respective status
is shown.
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and C-C motif family of chemokines. cxcl1, cxcl2, cxcl3, cxcl5, and cxcl6 showed
elevated levels in response to B. burgdorferi infection. In addition to their role in
modulating immune cell activation and inflammation, these chemokines provide a
mechanism for the chemotaxis of immune cells. Predominantly, the C-X-C family
possesses chemoattractant properties for leukocytes, such as neutrophils [124–
126]. In fact, Cxcl1 mediates the recruitment of neutrophils and subsequent
swelling in Lyme arthritis and carditis [127]. In contrast, the C-C family induces
the migration of PBMCs, including lymphocytes and monocytes [240]. In our
experiments, ccl2, ccl5, ccl13, and the receptor, ccr7, were found to be
upregulated. This is corroborated in a study that previously showed ccl2 (mcp-1)
and ccl5 (rantes) were elevated in human monocytes in response to B.
burgdorferi [241]. Ccr7, a receptor for Ccl19 and Ccl21, is constitutively
expressed in intestinal and gastric epithelial cells and has been shown to be
upregulated in response to Helicobacter pylori infection [242,243]. Biological
process analysis performed by GO, via STRING, indicates cytokine and
chemokine-mediated signaling pathways to be significantly enriched. Moreover,
processes involving the regulation of leukocyte and neutrophil chemotaxis were
shown to be enriched as well (Figure 2-5B). These observations are further
strengthened by SPIA, where the pathways cytokine-cytokine receptor interaction
and chemokine signaling pathways were found to be significantly enriched and
activated (Figure 2-7). Further evidence that may imply the immune trafficking
role of HCPECs comes from the secretion of these proteins at elevated levels
within the culture media, as previously stated (Figure 2-3B-E).
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B. burgdorferi Effects on Cellular Components Involved in Cell-Cell
Junctions and Adhesion
Although HCPECs were grown in a non-barrier monolayer culture, it was
found that a number of genes related to cellular junctions and adhesion were
modestly downregulated (Table II-2). The integrity of the BCSFB at choroid
plexus epithelium is contingent on the presence of several tight and adherens
junctions. Adherens junctions, found more basal than tight junctions (Figure II-1),
mainly involve cadherin proteins, for example E-cadherin, VE-cadherin, and Ncadherin [244]. The presence of CDH2 (N-cadherin) has been observed on the
basolateral side of the choroid plexus epithelium in mice [245]. Three genes
within the cadherin superfamily were found to be downregulated – cdh2, pcdh7,
and pcdh10. Likewise, genes that code for tight junction components showed
lowered expression – cldn14 and magi1. Genes within regulatory pathways that
promote the formation of these junctions or other cellular adhesins were also
found to have decreased expression – mtss1, atp1b1, and frmd4a. Network
analysis showed minimal clustering of genes involved in cellular adhesion
regarding protein-protein interactions (Figure 2-6A). Additionally, genes involved
in the modulation of surrounding extracellular matrix and vasculature were
observed to be downregulated, some of which shared overlapping function with
cellular adhesion – mmp1, flt1, vegfc, and serpine1. GO enrichment indicated
enriched cellular components that involve cell-cell junction and bicellular tight
junctions, as well as angiogenesis and epithelium development processes.
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Regulatory component

Functional
component

Table II - 2. Select genes involved in cell-cell junctions, tight junctions, and
adherens junctions.
Gene
Symbol
CLDN14
PCDH10

Log2 Fold
Change
-0.77849
-0.70536

p-value
(adjusted)
0.014354
0.000243

CDH2

-0.65003

3.70E-07

MAGI1

-0.42719

0.03935

PCDH7

-0.39693

0.011885

PODXL

-0.97617

6.91E-07

TWF1

-0.67896

0.038453

NEXN

-0.63395

0.015809

MTSS1

-0.53155

0.000231

FLT1

-0.50364

0.01255

ATP1B1

-0.47766

0.034878

MYLK

-0.43527

0.014211

CCND1

-0.37679

0.008102

FRMD4A

-0.3571

0.017093

CAPN2

-0.33762

0.047708

PALLD

-0.30542

0.041217

Function (Uniprot ID)
Tight junction protein; Cell adhesion (O95500)
Protocadherin; cell-cell adhesion (Q9P2E7)
Adherens junction protein; Cell adhesion
(P19022)
Scaffolding/Tight Junction Protein; Cell adhesion
(Q96QZ7)
Protocadherin; cell-cell adhesion (O60245)
Positive/negative regulation of cell adhesion
(O00592)
Actin binding; Cadherin binding; Focal adhesion
(Q12792)
Actin binding protein; Cell adhesion (Q0ZGT2)
Actin binding protein; Positive regulation of cellcell junctions, adhesion (O43312)
VEGF receptor; Endothelial proliferation, survival,
cell adhesion (P17948)
ATPase non-catalytic beta subunit; Cell adhesion;
Epithelial cell polarity (PO5026)
Regulates tight junctions; Regulates epithelial cell
survival, wound healing (Q15746)
Regulates cell cycle; Interactions with tight
junction proteins (P24385)
Scaffolding Protein – Regulates epithelial cell
polarity, adherens junctions (Q9P2Q2)
Protease; Negative regulation of junction and
adhesive pathways (P17655)
Scaffolding/Cytoskeletal protein; Cell adhesion
(Q8WX93)
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Pathway analysis indicates an inhibition of the focal adhesion pathway
(Figure II-7). The functional and structural impact of these downregulated genes
in response to B. burgdorferi infection is yet to be determined in an animal model.
Discussion
The neurological symptoms associated with Lyme disease are largely
attributed to the dissemination of Borrelia burgdorferi into the CNS and the
resulting host immune response. While previous studies have investigated the
effects of this bacteria on endothelial models of the BBB, little is known about its
impact on the epithelium of the choroid plexus which comprises the BCSFB. The
CP epithelium is situated at a key interface that separates the blood from the
CSF and has repeatedly been shown to play an important role in modulating the
immune response between the periphery and CNS during infection. The
importance of the composition of the CSF in regards to cytokines and infiltrating
immune cells in Lyme disease patients has been previously reported [76,84,246–
248]. However, in the context of Lyme disease, the choroid plexus has been
greatly understudied, and given its role as the major producer of CSF, as well as
its ability to regulate its composition, it constitutes a major gap in knowledge for
the pathophysiology of the disease [249]. To the best of our knowledge, this is
the first study to directly investigate the impact of Borrelia burgdorferi sensu lato
on choroid plexus epithelium.
This study demonstrates a robust change in gene expression in HCPECs
induced by B. burgdorferi infection. The most prevalent outcome was the
upregulation in immune and inflammatory response genes that were primarily
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categorized within the chemokine/cytokine mediated pathways and type I and II
interferon pathways. Consistent with our report, previous studies have observed
similar results regarding the inflammatory and immune response within
monocytes, macrophages, and dendritic cells, showing an increase in cytokines
such as cxcl1, cxcl2, ccl2, and ccl5 [250,251]. Likewise, interferon-stimulated
genes within a murine model were reported to be upregulated, involving the
transcripts Ifit1, Ifit3, and Irf7 [234]. Irf7 has been shown to be a master regulator
of interferon stimulated genes, and in conjunction with the upregulation of ddx58
(rig-I), ifih1 (mda4), and trim25, may provide insight into the activation of the
interferon pathway being observed. Additionally, the induction of inflammatory
cytokines including type I and type III interferons were reported when human
PBMCs were infected with B. burgdorferi [252]. Furthermore, when
characterizing the immunophenotypes of infiltrating immune cells and cytokines
within the erythema migrans (EM) lesions of patients, T cells, monocytes,
macrophages, and dendritic cells were found to be enriched in addition to
inflammatory cytokines [169].
While this study shows overlapping features common in other cell types or
animal models infected with Bb, the importance of the choroid plexus’s role in
immune cell trafficking is further highlighted in other models of infection and
disease. The concept of the immunosurveillance activity within the choroid plexus
is not new, and the abundance of immune cells found within the choroid plexus
and subsequent transmigration following infection or insult has been widely
reported [208,211,213,253,254]. Functional and pathway analysis indicates that
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many of these genes are involved in chemotaxis of immune cells [124,125,255–
258]. In fact, Cxcl1 (previously known as Kc) and Ccl2 (previously known as
Mcp-1) have been shown to mediate the recruitment of neutrophils into the joints
of mice infected with B. burgdorferi, and are required for the development of
Lyme arthritis [259]. The upregulation of cxcl1, cxcl2, cxcl3, ccl2, and ccl5, potent
chemoattractants for immune cells including neutrophils, monocytes, and T cells,
among others, have also been consistently reported to be elevated in other
bacterial infections of the CP. In a barrier model of the choroid plexus involving
infection with Neisseria meningitidis, in addition to an increase in these
chemoattractants, the recruitment and subsequent transmigration of
polymorphonuclear neutrophils and monocytes was observed [260,261]. Similar
results are also seen in response to Streptococcus suis, a gram-positive
bacterium that can be transmitted to humans from pigs, leading to symptoms
such as meningitis [262]. In a BCSFB model using human choroid plexus
papilloma cells, a viral infection with Echovirus 30 showed an enhanced
secretion of Cxcl1, Cxcl2, Cxcl3, and Ccl5 [263]. Indeed, when investigating the
composition of the CSF from individuals with B. burgdorferi induced
meningoradiculitis, an increase in inflammatory cytokines and a large number of
B cells and plasma cells are observed [264]. Collectively, the choroid plexus has
been shown to contribute significantly to the pathogenesis of many diseases and
in regards to Lyme disease, our data implies that the choroid plexus may play an
important role in the abundance of immune cell invasion of the CSF and the
exacerbation of CNS inflammation that is seen in patients [265,266].
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In our current model, our transcriptome analysis indicates a
downregulation of key tight junction and adherens junction genes, as well as
regulatory cell adhesion genes. cldn14, a tight junction protein associated with
the choroid plexus, as well as cdh2, an adherens junction protein, were found to
be downregulated [267,268]. The injection of LPS in mice to stimulate a
peripheral inflammatory response showed a similar gene expression pattern,
where the majority of upregulated genes within the choroid plexus involved
immune-mediated pathways, while downregulated genes participated in barrier
function, including claudins and protocadherins [269]. Though the functions of
protocadherins are still being fully elucidated, they have been found to play a key
role in cellular adhesion and barrier integrity [270,271]. In addition, the
sodium/potassium transporter beta subunit, atp1b1, was found to be
downregulated, yet, seems to be an unlikely participant in the formation of cellcell junctions; however, it has been shown to play an integral part in cell
adhesion and in both the formation and maintenance of tight junctions in
epithelial cells [272–275]. The downregulation of a number of these components,
as well as scaffolding and other regulatory genes such as magi1 and mtss1,
would indicate a potential dysregulation of the choroid plexus barrier. This may
lead to the possibility of immune cell invasion as well as an entry site for Borrelia
burgdorferi into the CSF. In fact, the choroid plexus has already been implicated
as a possible site of entry for both N. meningitidis and S. suis, specifically from
the basolateral side [276]. By using two in vitro barrier models constructed by
human brain microvascular endothelial cells (BMEC) and umbilical vein
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endothelial cells (HUVEC), Bb was found to differentially transverse these barrier
systems [89,277,278]. While B. burgdorferi was capable of crossing the HUVEC
monolayer, the traversal of the bacteria across the BMEC barrier required the
addition of plasminogen and was found to induce the expression of plasminogen
activators, receptors, and matrix metalloproteinases – supporting the concept
that the bacteria is able to utilize the fibrinolytic system which may promote its
dissemination through the degradation of the extracellular matrix and cell-to-cell
junctions [89,277,278]. However, in our experiments, we found conflicting results
– tissue plasminogen activator, tPA (plat), as well as its inhibitor, serpine1, were
both found to be downregulated. Furthermore, the metalloproteinases, mmp1,
and adamts15, were found to be downregulated and upregulated, respectively.
Though our system does not represent a barrier model, the observed outcome
lends credibility for our future studies involving B. burgdorferi infection in an in
vivo model to explore the impact of systemic infection on the BCSFB.
Conclusion
Following infection of HCPECs with Borrelia burgdorferi, we identified a
gene expression pattern that is marked by a robust increase in immune and
inflammatory genes within the cytokine/chemokine pathways and type I and II
interferon pathways. Protein analysis showed an enhanced secretion of these
inflammatory and chemotactic cytokines. Additionally, the downregulation of
genes involved in cell-cell adhesion, adherens junctions, and tight junctions was
observed. Overall, our data indicates that the choroid plexus, like in many other
infectious diseases, may play a key role in the pathogenesis of Lyme
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neuroborreliosis through the induction of inflammatory factors, the promotion of
immune cell migration, and potentially through the dysregulation of the BCSFB.
Our future studies will aim to elucidate the impact of B. burgdorferi infection on
the BCSFB integrity within an in vivo model. By understanding how the
inflammatory and immune response is modulated within the CNS, as well as
mechanisms by which Borrelia burgdorferi is able to traverse into the CNS, new
treatments for Lyme disease can be developed.
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CHAPTER III
DIFFERENTIAL METHYLATION IN HUMAN ASTROCYTES IN RESPONSE TO
BORRELIA BURGDORFERI SENSU STRICTO STRAINS
Introduction
The pathophysiology of Post-Treatment Lyme Disease Syndrome
(PTLDS) is currently unknown and many avenues remain to be explored.
Following treatment, 10-20% of individuals develop or experience a continuation
of symptoms that commonly include neurological involvement such as fatigue,
sleep disturbances, and cognitive difficulties. As some evidence has shown, the
peripheral immune response may indirectly lead to a deleterious state within the
CNS through the diffusion of inflammatory factors or migration of peripheral
immune cells across the blood-brain barrier and blood-CSF barrier. Additionally,
the direct involvement of resident immunity may lead to the exacerbation of
symptoms seen in patients, as B. burgdorferi has been shown to elicit a strong
inflammatory response within the CNS. Multiple studies have shown that both
live and heat or sonicated killed B. burgdorferi are capable of eliciting an immune
response in a wide variety of tissues, with spirochetal antigens being found in the
synovium of Lyme arthritis patients and in the CSF of neuroborreliosis patients
[76,279–282]. In fact, microglia and astrocytes, both resident glial cells of the
brain, produce an inflammatory response induced by B. burgdorferi [109,198].
Furthermore, the release of these inflammatory mediators has been implicated in
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neuronal apoptosis [80,151,283]. A more recent study in 2018 by researchers at
Johns Hopkins corroborated this role of glial activation in individuals with PTLDS.
By measuring the expression of the 18 kDa translocator protein (TSPO), a
mitochondrial protein that is greatly increased in activated microglia and reactive
astrocytes, through the use of a radiotracer ([11C]DPA-713) and positron
emission tomography (PET), the researchers were able to identify an increase of
this inflammatory marker in PTLDS patients [284]. Many of the symptoms
experienced by PTLDS patients are difficult to assess and are highly subjective,
however, these patients exhibit clinically significant levels of pain, sleep
disturbances, depression, and overall poorer quality of life [101]. As there are few
quantifiable abnormalities that can be measured in PTLDS, studies aimed at
investigating objective variables of the syndrome become even more important
for accurate diagnosis and clinical care that patients receive. Astrocytes are the
most abundant cell type in the brain, and due to their diverse roles and
implication to neuroborreliosis and PTLDS, they are the focus of the next two
chapters [199].
Astrocytes
Astrocytes, receiving their name from their star-like appearance, are highly
heterogeneous in their function and morphology. Through their numerous
processes, they form extensive intercellular networks that allow them to
communicate with each other through the formation of gap-junction channels
[285]. These networks extend to form neuro-glial connections that provide
nutritional support to neurons and, through the trafficking of metabolic substrates
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such as lactate, aid in sustaining neuronal activity during energy deprivation
[286,287]. Their relationship with neurons continues through their alterations of
neuronal synapses, by controlling their formation, removal, and the modulation of
neurotransmitters [288–292]. Additionally, with their specialized endfeet,
astrocytes are able to make physical contact with the endothelial cells of brain
vasculature, enveloping the CNS capillaries to aid in the formation, maintenance,
and function of the blood-brain barrier [293,294].
During neurological stress such as traumatic injury or disease, astrocytes
undergo a reactive state termed astrogliosis. This reactive state is marked by an
increase in proliferation, an increase in the length and number of processes, and
hypertrophy [295,296]. Intermediate filaments, which are prominent components
of the cytoskeletal system, are necessary for the morphological changes that
occur during astrogliosis [297]. Glial fibrillary acidic protein (GFAP), an
intermediate filament, is a standard marker for astrocytes, and the upregulation
of GFAP is a hallmark of astrocyte activation [298]. While the roles of astrocytes
during a healthy state are varied, the functions that follow astrogliosis are highly
diverse and context dependent. This is emphasized to such a degree that
reactive astrocytes may provide beneficial and protective roles in one scenario,
while becoming deleterious and cytotoxic in another [299–301]. In the context of
infection, reactive astrocytes become involved in the immune response by
modulating the inflammatory response in the brain [302]. Class II major
histocompatibility complex (MHC) are molecules that play an important role in the
immune response through the presentation of antigens and, the expression of
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MHC II is normally seen on professional antigen-presenting cells such as
macrophages, dendritic cells, and B cells. However, the expression of MHC II on
astrocytes has been shown to be induced by immune factors such as IFN-γ and
enhanced by TNF-α, and in fact, astrocytes were the first CNS cell type to be
shown to express MHC II upon IFN-γ stimulation [303,304]. In addition to their
antigen-presenting roles, in the context of diseases or infections, astrocytes are
able to secrete inflammatory cytokines and express chemokine receptors. These
can function as anti-inflammatory factors such as IL6 or IL10, or promote
inflammation such as CCL2, CCL5, CXCL1, and CXCL10 which lead to the
recruitment and activation of peripheral immune cells [305]. During infection,
astrocytes may encounter pathogen associated molecular patterns (PAMPS) that
are recognized by several receptors such as Toll-like receptors (TLRs).
Activation of TLRs results in a robust cytokine response that leads to a hostile
environment for resident cells [306]. This inflammatory state can disrupt the
homeostatic environment and lead to cytotoxicity [306–308]. As stated
previously, patients with PTLDS show an increased amount of glial inflammation
within the brain, and evidence has shown that astrocytes may contribute to
behavioral disturbances that are associated with inflammation, including
regulation of sleep, pain, and depression [284,309–312]. This is not surprising
when considering the broad functionality of astrocytes that allow them to regulate
the immune and inflammatory response, provide structural and nutritional support
including the blood-brain barrier, and modulate neuronal synapses.

75

A previous study by our laboratory investigated the effects of B.
burgdorferi on primary human astrocytes in vitro and found differentially
expressed genes that were involved in the immune response, structural and
cellular development, cell adhesion, and chromatin assembly [198]. As
inflammation is an important factor in the development of persistent symptoms of
PTLDS patients, and astrocytes have been shown to play an important role in
modulating this response in multiple diseases including Lyme disease, we sought
to investigate an alternative mechanism for the pathogenesis of PTLDS.
Therefore, we hypothesized that during infection, B. burgdorferi induces
epigenetic modifications in host cells that are conducive to a persistent
inflammatory state. The two epigenetic alterations that we have explored are
DNA methylation and chromatin accessibility, the former being the subject of this
chapter.
DNA Methylation
DNA methylation and its equally important counterpart, demethylation, is
the process in which methyl groups are added, or removed, to genomic DNA
(Figure III-1) [313]. In mammalian cells, DNA methylation occurs on cytosines at
position C5 and is predominately found in CpG dinucleotides [314,315]. DNA
methylation plays an important role in gene expression. When it occurs within
promoter or enhancer regions, it is typically associated with the silencing of gene
expression; however, current evidence suggests that the opposite may be true
when it occurs within the gene body, that methylation within the gene body is
positively correlated to transcription [316–319]. As such, DNA methylation is
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Figure III - 1.

DNA methylation and its effects on gene transcription.
(A) Schematic of DNA methylation depicting the process
whereby a methyl group is transferred to cytosine by a DNA
methyl transferase (DNMT1, DNMT3A, DNMT3B). (B) The
effects of DNA methylation on gene expression is an on-going
project. Methylation within the promoter region leads to a
silencing of that gene. While methylation within the gene body
seems to promote gene transcription.
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fundamental to several important processes including normal development,
genomic imprinting, X chromosome inactivation, and cell differentiation [315,320–
324]. DNA methyltransferases (DNMTs) are enzymes that catalyze the transfer
of a methyl group to cytosine. The main function of DNMT1 is methylation
maintenance, and it has been shown to preferentially act upon hemimethylated
CpGs, typically during DNA replication [325]. During DNA replication, DNMT1
copies the methylation pattern to the newly synthesized strand [326,327]. In
contrast, DNMT3A and DNMT3B function in de novo methylation and act upon
unmethylated DNA, though this function may also aid in the maintenance of
methylation patterns that were not established by DNMT1 [322,328–330].
Following fertilization, parental genomes of the zygote undergo dramatic
demethylation, and in fact, the paternal genome in mice undergoes significant
active demethylation within 6-8 hours of fertilization, while maternal genome
demethylation occurs after several cleavage divisions [323]. De novo methylation
by DNMT3A and DNMT3B re-establishes the DNA methylation pattern following
this demethylation stage and is in part responsible for cellular-specific
differentiation [331,332].
Upon microbial invasion, host cells undergo large transcriptional changes
that involve genes associated with immunity, inflammation, cellular
protection/apoptosis, adhesion, and motility. It is therefore not surprising that
such changes in gene expression are not only dependent on transcription factors
but epigenetic alterations that provide transcriptional regulation through
chromatin accessibility and DNA methylation. Bacterium-induced epigenetic
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modifications have gained attention in recent years as mechanisms that underlie
the host defense response [333]. DNA methylation alterations in response to a
pathogen have been best documented in H. pylori infections. H. pylori, best
known to cause gastric ulcers, as well as gastric cancer, has been shown to
cause aberrant DNA methylation in human gastric mucosa. Notably, this
occurred at the promoters of genes that were previously found to be methylated
in gastric cancer cells, such as hypermethylation of tumor-suppressor genes (e.g.
USF1/2) and DNA repair genes (e.g. MLH1) [334–338]. Furthermore, epigenetic
regulation of the inflammatory response in infection and chronic inflammatory
diseases has garnered greater attention in recent years [333,339]. These
alterations to the epigenetic landscape may have lasting effects and lead to
epigenetic memory or “imprinting” on the genome. Evidence of this epigenetic
imprinting is found following the removal of H. pylori infection in human patients,
in which a decrease but not a return to basal levels of methylation is seen in the
promoter regions of genes associated with the risk of gastric cancer [340].
As epigenetic alterations are continuing to be researched in association
with bacterial infections, we sought to investigate the role of B. burgdorferi as an
epimutagen, which could be further investigated as a potential mechanism for the
persistent symptoms seen in PTLDS patients. To this end, we utilized primary
human astrocytes grown in culture, which were then subjected to B. burgdorferi
infection. The methylome was then profiled through the Illumina beadchip array.
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Materials and Methods
Bacteria culture
Three strains of B. burgdorferi sensu stricto were used throughout the
experiments based on infectivity: B31-e2, a high-passage-number noninfectious
clone of B31 tick isolate; B31-MI-16, an infectious clone of B31; and 297, an
infectious and suspected neurotropic isolate from the CSF of a Lyme disease
patient [19,20,85,217,341,342]. All strains were grown and utilized in an identical
manner. Bacteria cultures were grown in modified Barbour-Stoenner-Kelly (BSKII) medium supplemented with 6% rabbit serum at 34°C to approximately 1 x 107
bacteria/ml and used at passage 2 [343,344].
Cell culture
Primary human astrocytes were obtained from ScienCell Research
Laboratories (catalog # 1800). Cultures were maintained in tissue-treated vented
cap T-75 flasks (Corning, catalog #430641U) in astrocyte cell medium
(ScienCell, Catalog #1801) that was supplemented with 1% astrocyte growth
supplement (ScienCell, Catalog #1852), 2% fetal bovine serum (ScienCell,
Catalog #0010), and antibiotics penicillin and streptomycin at a final
concentration of 100 units/ml and 100 ug/ml, respectively (ScienCell, catalog
#0503). Cells were incubated at 37°C and used at passage 3 at approximately
80% confluency for B. burgdorferi infection. Prior to the addition of B. burgdorferi,
cell cultures were washed 3 times with sterile Dulbecco’s phosphate buffered
saline (DPBS) and new antibiotic-free astrocyte medium was added to the
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cultures. Light microscopy was used to monitor cell morphology and confluency
before and after infections.
Infection
Cell cultures were stimulated with either B. burgdorferi B31-e2, B31-MI-16,
or 297 at a multiplicity of infection (MOI) of 10:1 (bacteria:cells) for 24, 48, 72,
and 92 hours. Global methylation arrays were performed on astrocytes infected
with B31-e2 and B31-MI-16. To achieve an appropriate MOI, the mean cell count
of astrocytes was determined using an automated cell counter (Life Countess II,
catalog #AMQAX1000). The control group was prepared identically without B.
burgdorferi infection.
DNA Isolation and Differential Methylation
For both the global DNA methylation assays and the Illumina Infinium
MethylationEPIC beadchip array, DNA was isolated from samples using DNeasy
Blood and Tissue kit from Qiagen (Qiagen, catalog #69506) according to the
manufacturer’s instructions. Briefly, culture supernatant was removed to be used
for protein analysis, and cultures were washed 3 times with DPBS. Following
washes, cells were collected using Trypsin (ThermoFisher, catalog #15050065),
centrifuged for 5 min at 300 x g at 4°C, and supernatant was aspirated from the
cell pellet. The pellet was then resuspended in PBS, and proteinase K and
RNase A were added. Cells were then fully lysed, and the resulting mixture was
added to the DNeasy spin columns. Following subsequent washes, RNA-free
genomic DNA was eluted in 100 ul of nuclease-free water. Initial DNA
concentration and quality was assessed by NanoDrop.
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Samples were submitted to the University of Minnesota Genomics Center
for differential methylation analysis using the Illumina Infinium MethylationEPIC
BeadChip array. The array queries 850,000 individual CpG sites in the human
genome. Prior to this, samples underwent further QC which included PicoGreen
DNA quantification and QC1 assay, a q-PCR based assay to assess impurities.
All samples passed quality control. Samples were then subjected to DNA bisulfite
conversion, in which unmethylated cytosines are converted to uracil and
methylated cytosines remain. Through this method, single-nucleotide resolution
of CpG methylation can be obtained via the Illumina Infinium MethylationEPIC
BeadChip. Data analysis was performed by the University of North Dakota
Genomics Core at the School of Medicine and Health Sciences.
Global Methylation was assessed using the MethylFlash Global DNA
Methylation (5-mC) ELISA Easy Kit (Colorimetric) (EpiGentek, Catalog #P-03048), according to manufacturer’s instructions. In short, this assay provided a onestep ELISA-like reaction in which the DNA is bound to a 96 well-plate, capture
and detection antibodies for methylated DNA were added, and the resulting
signal was quantified colorimetrically using a BioTek Epoch plate reader. Infected
groups at each time point were compared to uninfected control groups by a
Student’s t-test. Significance was determined if p < 0.05.
Protein Analysis of Supernatant by ELISA
Supernatants from cultures were removed as previously mentioned
following treatment. ELISAs were performed following manufacturer’s instructions
(R&D Systems, DuoSet ELISA). In short, 96 well plates were coated with capture
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antibody and incubated overnight at room temperature. The antibody was then
aspirated, and wells were washed, followed by the addition of 100 ul of standard
or sample to each well. Following incubation at room temperature for 2 hours and
subsequent aspiration of samples, a conjugated detection antibody was added.
The addition of a chromogenic substrate and stop solution allowed for
colorimetric detection on a BioTek Epoch plate reader.
Results
Global Methylation
Our initial investigation into differential methylation caused by B. burdorferi
involved assessing changes in global DNA methylation by using the Epigentek
global methylation assays. Primary human astrocytes were cultured and infected
with either B31-e2 or B31-MI-16 for 24, 48, 72, and 96 hours (n=3 for each
group). As B31-e2 is a non-infectious strain, it was used to determine changes in
global methylation that were associated with infectivity when compared to B31MI-16. No significant changes in global methylation were found at any time points
for astrocytes infected with B31-e2 when compared to control groups and no
morphological changes were observed under light microscopy (Figure III-2A). For
infection with B31-MI-16, no significant changes in global methylation were found
in 24, 48, and 72-hour time points and no morphological changes were apparent.
However, a significant increase in global methylation was observed at 96 hours,
resulting in approximately a 0.6% increase in methylation (Figure 3-2B). An
overall increasing trend in global methylation can be seen in astrocytes infected
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Figure III - 2.

Changes in global DNA methylation in astrocytes in response to
infection.
Astrocytes were infected with either B. burgdorferi strain B31-e2
or B31-MI-16 for 24, 48, 72, and 96 hours. (A) Infection with e2
showed no significant changes in global DNA methylation in
astrocytes. (B) Infection with MI-16 showed a general increase in
global DNA methylation, and a significant increase at 96 hours
compared to control. No morphological changes in astrocytes
were observed in either infection, based on light microscopy.
Statistical testing was done by Student’s t-test, and significance
was set at p < 0.05.
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with B31-MI-16, however, this trend is not observed in cells infected with B31-e2,
as changes in methylation seemed more sporadic.
The data obtained from these sets of experiments were limited by the high
variance between biological replicates, as observed in the plotted error bars of
the standard deviation. This variability was exacerbated by the low replicate
number and could be ameliorated by an increase in replicates. At this point in the
experimentation, we evaluated the cost-benefit of these set of experiments in
regard to the relevance and importance in further investigating global
methylation. Though we were able to detect a significant change in global
methylation in the 96-hour time point of B31-MI-16 infected group, and no
change in the B31-e2 groups, this data provided little insight. As these assays
assessed the global methylation status within astrocytes, it provided no
specificity in the regions or genes that were altered. Furthermore, and of greater
importance, changes in global methylation or lack thereof, cannot be determined
as biologically relevant. In other words, the lack of global methylation changes
that were seen in all but one group does not negate the possibility that region
specific methylation changes are occurring, e.g. if one gene becomes
hypermethylated, while another gene becomes hypomethylated, this may be
correlated to a drastic transcriptional change, but global methylation is not altered
overall. Due to this, we felt pursuing genome-wide CpG specific analysis would
provide a greater outcome.
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Microarray Methylation Profiling
Similar to our global methylation experiments, we assessed the alterations
to specific CpG’s in astrocytes infected with either B31-e2, B31-MI-16, and 297
for 24, 48, 72, and 96 hours. A total of 9 biological replicates were used for each
group except for 297 which contained 3 replicates as it was a late addition to the
experiments. These biological replicates came from 3 separate primary samples
(e.g. samples taken from 3 different individuals), except for 297 which came from
a single primary sample. Following these infection time points, the supernatant
was collected for protein analysis and DNA was isolated from cells. To determine
if astrocytes responded to infection as expected, protein analysis of the
supernatant was first assessed by ELISA for the following factors: Serpin G1, IL6, CCL20, CXCL1, and CXCL8 (Figure III-3). These proteins were chosen for
their function in immunity and their differential regulation that was observed in the
previous study performed in our laboratory regarding astrocytes [198]. SerpinG1,
also known as C1-inhibitor, functions to inhibit the complement system – no
significant changes were seen across time points and strains when compared to
control. Similarly, IL-6, an interleukin that can act as both pro- or antiinflammatory, and CCL20, a chemotactic for peripheral immune cells, were not
seen to be significantly altered. CXCL1 and CXCL8, neutrophil activator and
attractant, respectively, were found to be significantly upregulated in a number of
groups. Astrocytes infected with either MI-16 and 297 saw a significant increase
in these factors at later time points, 72 and 96 hours, while 297 also elicited a
significant response at 48 hours. Infection with e2 seemed to stay at basal levels
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Figure III - 3.

Analysis of cytokine production by astrocytes infected with
B. burgdorferi.
The supernatant from cell cultures was collected following
infection with either B. burgdorferi strain B31-e2, B31-MI-16, or
297 for 24, 48, 72, and 96 hours, and were analyzed by ELISA.
Serpin G1, IL-6, CCL20, CXCL1, and CXCL8 were analyzed and
were chosen for their role in the immune response. Strain
specific and time effects were as expected. In general, e2
remained at similar levels as control. MI-16 and 297 produced
similar effects at slightly different magnitudes. Serpin G1, IL-6,
and CCL20 showed no significant changes. Infection with MI-6
and 297 produced a significant increase in CXCL1 and CXCL8 at
72 and 96 hours, while 297 also induced an increase in CXCL8
at 48 hours.
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relative to the control. Interestingly, 297, a potentially more neurotropic strain,
showed a generally larger response than MI-16. These data, specifically
regarding CXCL1/8 indicated that our infections led to an expected immune
response from astrocyte cultures.
Following these experiments, DNA samples were pooled according to
strain and time point, but primary samples remained separate, to be sent for
methylation profiling – this was necessary to reduce cost but still maintain an
appropriate replicate number. Table III-1 indicates the samples that were
submitted. Data analysis was performed by the University of North Dakota
Genomics Core – differential methylation was considered significant with an FDR
< 0.05. Surprisingly, there were no significant differentially methylated regions
across any time points or strains compared to control which immediately raised
concerns. DNA samples were isolated from the same samples that the
supernatant was collected from, which showed a general response to infection
with B. burgdorferi, as well as being strain specific. Additionally, all DNA samples
passed QC within our laboratory, QC within the UND genomics core, and QC
within the University of Minnesota Genomics Center. Figure III-4A depicts
selected histograms of the adjusted p-values of infected groups compared to
control. All reads were greater than the significance threshold of FDR < 0.05. A
multidimensional scaling plot (MDS plot) is a method to visualize the similarity of
all samples with each other. Through this we can visualize how each treatment
clusters together e.g. do samples infected with 297 cluster more closely to
samples infected with MI-16 than with e2 infected groups? When an MDS plot
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Table III - 1. Sample submission
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Figure III - 4.

A representative overview of DNA methylation profiling results.
Following infection, astrocyte DNA was isolated and DNA
methylation profile of each sample was analyzed by Illumina
MethylationEPIC array. (A) Histograms indicating adjusted pvalue frequency at e2 96 hours and MI-16 96 hours,
representative of all other groups. No significant changes in DNA
methylation were observed in any strain or time group. Maximum
frequency of p-values neared a p-value of 1.0.
(B) Multidimension scaling plot (MDS) by biological replicate and
B. burgdorferi strain. As no significant results were found, an
explanation was sought. The MDS plot by biological replicate
explains a major reason for this – large variability between
replicates exist due to biological replicates being obtained from
three different primary samples. The MDS plot by strain indicates
that greater similarity exists between strain and time point than
between biological replicates.
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was generated for our samples, we expected similarities to occur based on
infectivity of the strain and/or time points. However, as seen in Figure 3-4B, all
samples densely clustered according to their biological replicate. This was a
clear indication that the variability between primary samples was far greater than
anticipated and was to such an extent that the effects of B. burgdorferi strain and
duration of infection had no significant impact on DNA methylation when
compared to controls. Additionally, biological replicate 1 was male, while
replicates 2 and 3 were female and seemed to cluster slightly closer together.
In order to control for the variability between biological replicates,
biological replicate 1 was removed and a number of comparisons were made. A
summary of these comparisons and results are seen in Table III-2. Removal of
the first biological replicate provided minimal number of differential methylation
CpGs. Many of the differentially methylated regions were not associated with any
gene, let alone within the gene itself. A gene that commonly came up across
multiple comparisons that was associated with was C4orf22, also known as ciliaand flagella-associated protein 299 (CFAP299), which has no well-known
function but is predicted to play a role in spermatogenesis [345].
Pooling MI-16 and e2 groups together provided the most robust change in
methylation that was seen at 24 hours. It is uncertain the biological relevance of
this change, as the pooling of the non-infectious strain B31-e2, which previously
did not induce a response in astrocytes at the protein and methylation level,
would not be expected to have any significance. Nevertheless, a total of 91
differentially methylated CpGs were observed, with 78 being methylated and
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Table III - 2. Summary of differential methylation comparisons
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13 unmethylated. Table III-3 displays genes of interest that contained a
differentially methylated CpG. Neuronal growth regulator 1 (NEGR1) shown to be
differentially methylated within the body of the gene – suggesting an upregulation
to gene transcription. NEGR1 is associated with neurogenesis as well as
behavior disorders, intellectual disability, and depression [346–348]. Another
gene associated with an increased CpG methylation was Myosin-9 (MYH9),
which encodes the heavy chain of non-muscle myosin of class II, isoform A
protein (NM IIA). NM IIA is found in most cell types and participates in a number
of functions that include cytokenisis/proliferation, cell migration and motility,
maintenance of cell shape and polarization, and adhesion [349,350]. However,
the methylation occurred within the 5’ untranslated region (UTR) of the gene,
which may lead to an increase in gene transcription but has also shown
conflicting correlation to gene expression; it may also play a role in translation
[351–353]. Additionally, STX8, SNX33, and DYM are genes that have functions
in cytoskeletal restructuring, endocytosis, cellular vesicle trafficking, and
secretory pathways [354–360]. All methylated regions predict an upregulation in
gene expression.
Two main functions of astrocytes may be altered in response to infection
within this same comparison group: neurotransmitter uptake, specifically
glutamate, and the regulation of the immune response. An increase in
methylation was found within three genes within the solute carrier family:
SLC1A3, SLC20A2, and SLC22A23. SLC1A3 and SLC22A23 contained a
methylated CpG within the body of the gene, associated with an increase in gene
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Table III - 3. Selected methylation sites
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expression; transcription of SLC20A2 is less known as methylation occurred with
the 5’ UTR. The solute carrier family is a family of transmembrane proteins that
function as transporters across cell membranes. Of interest is SLC1A3 as it
encodes for the protein excitatory amino acid transporter 1 (EAAT1), which is
also commonly called glutamate aspartate transporter 1 (GLAST-1). It is found
throughout the CNS and is highly expressed in astrocytes [361–363]. GLAST-1 is
a glutamate transporter that functions to maintain the extracellular glutamate
concentrations, an important function that aids in regulating neuronal function as
glutamate is a major neurotransmitter [362]. Through these functions, astrocytes
are the key players in glutamate regulation and thus are able to modulate
synapse function and protect from excitotoxicity of neurons that may occur if
extracellular glutamate concentrations are too high [364–366]. Dysregulation in
glutamate concentrations is associated with a number of deleterious outcomes.
Glutamate-induced excitotoxicity can lead to a decrease in neuronal regeneration
and dendritic branching, as well as behavioral alterations that follow [367–369].
This potential upregulation of SLC1A3 through the methylation of the gene body
would suggest a neuroprotective effect following B. burgdorferi infection. This
“protective effect” also extends to the methylation within the gene body of NF-κB
inhibitor alpha (NFKBIA, also known as IκBα), which would have a predicted
upregulation in gene expression. The protein functions as an inhibitor to the wellknown transcription factor NF-κB, which itself is a major player in the proinflammatory signaling pathway [370]. However, the NF-κB pathway has been
shown to play many different roles that are context dependent, and as there is a
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major dichotomy in CNS inflammation as being beneficial or deleterious, it is
difficult to label such an effect as being “protective”. Interestingly, another role of
NF-κB appears to be the downregulation of GLAST1 expression, through the
ERK/PI3K/NF-κB signaling pathway, induced by tumor necrosis factor-α (TNF-α)
[364,371,372]. Therefore, NFKBIA may provide a pathway for the upregulation of
GLAST1 (SLC1A3). Finally, phosphodiesterase 7A (PDE7A) has been
associated with immunity and inflammation and may be required for T cell
activation, though this requirement may be overstated [373–376]. Regardless,
demethylation was found in the gene body of PDE7A, associated with
downregulation of the gene. Unfortunately, no other comparisons that were made
provided a substantial or relevant change in methylation.
Discussion
Minimal changes were noted across comparisons of B. burgdorferi strains
and time points. However, through the removal of replicate 1 that showed the
most dissimilarity compared to the other two replicates, additional insight was
gained. Increasing statistical power through the pooling of MI-16 and e2 infected
groups provided the most robust change when compared to control at 24 hours.
Taking into consideration the effects of methylation on gene transcription,
astrocytes seemed to respond to infection in several ways. Genes associated
with cytoskeletal restructuring and cellular trafficking are predicted to be
upregulated and may be associated with changes in morphology, secretion, and
cell proliferation, suggesting that astrocytes may be undergoing astrogliosis. One
of the major functions of astrocytes is the structural and trophic support of
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neurons, specifically the modulation of the neurotransmitter glutamate. Three
members of the solute carrier family were found to be affected. SLC1A3 encodes
for a major glutamate transporter, GLAST1 and is responsible for maintaining a
homeostatic environment of extracellular glutamate. This is important to prevent
the excitotoxicity of neurons that have been associated with a number of
neurological disorders. Additionally, there seem to be conflicting results regarding
immunity and inflammation, with the predicted upregulation of NF-κBIA and
PDE7A. The CNS is a tightly regulated system that requires strict control of the
resident immune response in order to maintain functionality. This is compounded
by the dual nature of inflammation – during infection, an inflammatory response
aids in the destruction and clearing of a pathogen; however, as seen in Lyme
disease, specifically PTLDS, prolonged inflammation plays a major role in the
pathogenesis of these symptoms. Determination of gene expression is uncertain
and furthermore, the phenotypic outcome is difficult to predict. However, taken
together, a generous assumption would state that it does seem that infection with
B. burgdorferi may cause alterations to DNA methylation that could lead to
phenotypic characteristics associated with PTLDS, but due to many limitations of
the data, these results must be understated.
As highlighted previously, the major issue in the generation of relevant
data lies in the variability of our biological replicates which came from three
different primary samples. In hindsight, this can be seen in the large error bars of
our ELISA experiments. In order to overcome this, we have changed our
methodology for future experiments utilizing primary samples, such that
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biological replicates stem from the same primary sample i.e. obtained from a
single individual. With that said, other methods of data analysis within our current
data set could provide additional information. Two methods could be adopted. As
each biological replicate clusters within itself, analysis of each replicate
individually could be done. The obvious limitation to this would be that each data
set would only have an N of 1, so the lack of statistical power would limit
statistically significant results. However, data obtained through this method could
provide understanding into the variability of symptoms of Lyme disease patients,
and why some individuals have a poor prognosis while others seemingly recover
without ill-effects.
The second method to reevaluate our data set can be applied to both
circumstances. As seen in our dataset, methylation occurs at single CpGs, and
no gene showed multiple CpG differential methylation. This is another factor that
should be taken into consideration when discussing the biological significance of
our results. While the methylation of gene regions can be associated strongly
with either up or down gene expression (e.g. promoter methylation results in
down-regulation), it is not clear what a change in methylation of a single CpG
would result in. One method to ameliorate this would be to bin the genome into
specific regions. For example, the methylation of the entire promoter region of a
gene would be compared between treatment groups. This would potentially
provide a larger number of statistically significant differentially methylated regions
and provide the much-needed context in relation to gene transcription.
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Though our experiments were not as fruitful as we had anticipated, the
importance of research into the epigenetics of infections continues to grow. With
the advent of newer sequencing technologies, the price of performing these
experiments are being rapidly reduced. Thus it is hopeful that this topic can be
reexamined in the context of Lyme disease, and as new therapeutics are being
developed to target epigenetic markers, such work will become even more
significant [377–380].
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CHAPTER IV
INVESTIGATING THE CHROMATIN STRUCTURE OF HUMAN ASTROCYTES
IN RESPONSE TO BORRELIA BURGDORFERI SENSU STRICTO STRAINS
Introduction
The human genome consists of approximately 6 billion base pairs, and the
genome of a single cell would span roughly two meters. To cope with the
physical size needed to fit within the nucleus, DNA is orderly packaged and
condensed into chromatin, a complex of DNA and protein. This organization of
the genome facilitates cell division and aids in regulating gene expression and
DNA replication. At its core, the main protein component of chromatin are
histones that condense DNA into a basic structural unit called nucleosomes.
Nucleosomes consist of ~147 bp of DNA wrapped around a histone octamer
core, which consists of two copies of each of the four histone proteins, H2A,
H2B, H3, and H4 [381,382]. This tightly condensed chromatin, also called
heterochromatin, is poorly conducive to gene transcription; however, chromatin is
a highly dynamic structure that can be regulated to allow for more optimal
accessibility to transcription factors and thus gene transcription. This lightly
packed and more accessible structure, also called euchromatin, resembles
beads on a string and allows for the binding of regulatory proteins and RNA
polymerase to DNA.
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A predominant mechanism that allows for the regulation of chromatin
structure is the post-translation modification of histones. These modifications
typically occur on the N-terminal tails of the histones. There is a wide range of
modifications that can occur, including citrullination, phosphorylation,
SUMOylation, and ubiquitination. However, some of the most well-studied
modifications and those that are of interest to this study are methylation and
acetylation [383,384]. Through these modifications, the interactions between
histones and DNA can be altered, thus leading to chromatin restructuring and
modulation of gene transcription [385]. Many modifications and their impact on
chromatin structure have been investigated, making up a so-called “histone
code” through the combinatorial effects of these modifications [386,387]. Some of
these modifications and their subsequent impact of chromatin include –
H3K4me1: Activation, H3K4ac: Activation, H3K9me1: Activation, H3K9me3:
Repression, H3K27me3: Repression, and H3K27ac: Activation [387–391]. As
this is such a significant and global system for regulation of gene transcription, it
has spanned across all fields of research including infection. Many studies have
shown that bacterial products such as LPS or host secreted factors such as IFNγ can induce histone modifications and therefore chromatin restructuring. This is
true for Helicobacter pylori and its secreted factor HP0175 which activates TLR4
and induces NF-κB, ERK, and p38 MAPK activation leading to subsequent
histone acetylation and IL-6 production [392,393]. Similarly, Listeria
monocytogenes has been shown to induce similar pathways leading to
alterations in the phosphorylation of H3S10 and H4 acetylation [394,395]. Of
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further relevance to the data presented in this chapter, many of these effects
occur through the activation of TLRs and associated transcription factors within
the AP-1 complex including JUN and ATF [333,392,396–398].
We sought to investigate the astrocytic response to B. burgdorferi and its
impact on chromatin structure and histone modifications. As such, we
hypothesize that infection with B. burgdorferi leads to chromatin remodeling that
is conducive to a deleterious inflammatory response and dysregulation of normal
astrocytic functions. Our experimental design utilized primary human astrocytes
in culture and infected with B. burgdorferi for four time points: 24, 48, 72, and 96hours. Through these time points, we aimed to determine temporal and therefore
dynamic alterations in chromatin accessibility. By using the Assay for
Transposase-Accessible Chromatin (ATAC) sequencing, we aimed to achieve a
global profile of these changes. Furthermore, we had simultaneously performed
identical experiments to provide material for further correlation to gene
expression and histone modifications by RNA-seq and ChIP-PCR/Seq,
respectively. Unfortunately, due to technical shortcomings, we had only achieved
minimal coverage via ATAC-seq and therefore we did not continue further
investigation. The data presented in this chapter covers our findings of our
ATAC-seq, highlighting these dynamic changes in the chromatin accessibility and
the potential impact of gene expression.
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Materials and Methods
Bacteria Culture
Borrelia burgdorferi strain B31-MI-16 was used for infection. Cultures were
grown in modified Barbour-Stoenner-Kelly (BSK-II) medium supplemented with
6% rabbit serum at 34°C to approximately 1 x 107 bacteria/ml and used at
passage 2 [343,344].
Cell Culture
Primary human astrocytes were obtained from ScienCell Research
Laboratories (catalog # 1800). Cultures were maintained in tissue-treated vented
cap T-75 flasks (Corning, catalog #430641U) in astrocyte cell medium
(ScienCell, Catalog #1801) that was supplemented with 1% astrocyte growth
supplement (ScienCell, Catalog #1852), 2% fetal bovine serum (ScienCell,
Catalog #0010), and antibiotics penicillin and streptomycin at a final
concentration of 100 units/ml and 100 ug/ml, respectively (ScienCell, catalog
#0503). Cells were incubated at 37°C and used at passage 3 at approximately
80% confluency for B. burgdorferi infection. Prior to the addition of B. burgdorferi,
cell cultures were washed 3 times with sterile Dulbecco’s phosphate buffered
saline (DPBS) and new antibiotic-free astrocyte medium was added to the
cultures. Light microscopy was used to monitor cell morphology and confluency
before and after infections.
Infection
Cell cultures were infected with either B. burgdorferi B31-MI-16 at a
multiplicity of infection (MOI) of 10:1 (bacteria:cells) for 24, 48, 72, and 92 hours.
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To achieve an appropriate MOI, the mean cell count of astrocytes was
determined using an automated cell counter (Life Countess II, catalog
#AMQAX1000). Bacterial cultures were manually counted using a PetroffHausser Counting Chamber (Hausser Scientific, catalog #3900) and dark field
microscopy. The control group was prepared identically without B. burgdorferi
infection. N=3 for all groups.
ATAC-seq
ATAC-seq was performed as previously described [399]. Following
infection, cultures were washed with DBPS and harvested by trypsinization. Cell
viability and cell number were determined to be >95% by trypan blue staining and
automated counting. A fundamental aspect of ATAC is the need for only a small
number of cells – following viability and counting, 50,000 cells were isolated and
centrifuged. Cells were centrifuged at 500g at 4°C for 5 minutes. The supernatant
was aspirated and 25 ul of CSK lysis buffer (10 mM PIPES, pH 6.8; 100 mM
NaCl; 300 mM sucrose; 3 mM MgCl2; 0.1% Triton X-100) was added to the cell
pellet for nuclei isolation and placed on ice for 5 minutes. The presence of
isolated nuclei was checked using trypan blue and light microscopy. Prior to this,
optimization of lysis buffer was determined – astrocytes were subjected to either
Greenleaf lysis buffer (10 mM Tris-HCl, pH 7.4; 10 mM NaCl; 3 mM MgCl2; 0.1%
(v/v) Igepal CA-630) or CSK; using trypan blue and light microscopy, it was
determined that CSK was a more efficient buffer for nuclear isolation, as a
greater percentage of nuclei were observed. Following lysis, nuclei were pelleted
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at 500g at 4°C for 10 minutes, supernatant was aspirated, and the resulting pellet
was placed on ice.
For the transposition step of ATAC, the Nextera DNA library preparation
kit was used (Illumina, catalog #FC-121-1030). 50 ul of the transposition mix (25
µl TD 2x reaction buffer, 2.5 µl TDE1 Tn5 Transposase, and 22.5 µl nucleasefree water) was added to the nuclei pellet and resuspended. The transposition
reaction was incubated at 37°C for 30 minutes. The reaction was then purified
using Qiagen MinElute PCR Purification Kit according to the manufacturer’s
instructions (Qiagen, catalog #28004) and DNA was eluted using Buffer EB (10
mM Tris-Cl, pH 8.5). Transposed DNA was then amplified by PCR. In short,
primers from the Nextera Index Kit (Illumina, catalog #FC-121-1011) were
selected to provide unique indexing of each sample during PCR amplification,
and PCR master mix from NEB (NEB, catalog #M0541S) was used. Thermal
cycle settings were followed according to Buenrostro et al [399]. The amplified
library was purified again using the Qiagen MinElute PCR Purification Kit and
eluted in Buffer EB (10 mM Tris-Cl, pH 8.5).
Quality control of samples was performed by the University of North
Dakota Genomics Core. DNA libraries were placed in an Agilent 2100
Bioanalyzer with the Agilent High Sensitivity DNA Kit (Agilent, catalog #50674626) to assess DNA fragment size and quality. Concentrations of samples were
determined by a BioTek Gen5 Wellplate reader with the Quant-iT Picogreen kit
(ThermoFisher, catalog #P11496). Initial concentrations of most samples were
below the recommended concentration of 3nM. The concentration was increased
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by reducing the volume of samples using a speed-vac. Again, samples were
subjected to the well plate reader, and sufficient concentrations were established.
Samples were sent to Novogene and an Illumina HiSeq 4000 was used for 150
bp paired-end sequencing across two lanes.
Data Analysis
Data was received from Novogene in FASTQ format. Initial quality control
of raw data was performed by FastQC. Adaptor and low-quality base trimming
were performed by trimmomatic, followed again with a quality check by FastQC –
all samples passed. Alignment to the human (hg19) assembly was performed by
Hisat2, version 2.1.0 and indexed by Samtools, version 1.9. Insert size
calculation was performed by Picard, specifically the collectinsertsize tool,
version 2.20.2. As expected, sub-nucleosome insert size (<150bp) was most
predominantly enriched, with minor enrichment at mono-nucleosome (150200bp) and di-nucleosome (200-400bp) insert sizes. As mitochondrial DNA do
not form histone complexes, mitochondrial reads are typically non-negligible in
ATAC-seq experiments [400]. Mitochondrial reads were removed by
removeChrom.py (J. M. Gaspar; https://github.com/jsh58/harvard/blob/master/
removeChrom.py). PCR artifacts, such as duplicate reads, can arise during
ATAC-seq. Duplicate reads were flagged by Picard – Markduplicates, and
removed during peak calling. Peaks were called by MACS2, version 2.1.2 [401].
Differential peak analysis was performed by DiffBind on the output peak
files obtained by MACS2 [402]. To determine differential peaks, the following
comparisons were made: 24hr infected vs control, 48hr infected vs control, 72hr
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infected vs control, and 96hr infected vs control. DiffBind produces a consensus
peakset, which are peaks shared between a minimum number of samples. In this
analysis, a peak that was found in at least two samples was considered to be
within the consensus peakset. Diffbind utilizes DESeq2 to perform differential
analysis between groups that are being compared. Although the number of reads
differ between our samples, DESeq2 performs read count normalization to
alleviate this issue. Furthermore, the Benjamini-Hochberg adjustment is a posthoc statistical test that is applied to our initial p-values, which produces a falsediscovery rate (FDR). This adjusted p-value, or FDR, was set at < 0.05 for
statistical significance. Each comparison produced a differential peakset.
Additional analysis was performed to find overlapping differential peaks between
datasets as well as to identify unique differential peaks in each condition. Using
these differential peak sets, the DiffBind contrast and overlapping functions
allowed us to compare differential peaksets across each group; a Venn diagram
was produced to summarize these findings. To annotate peaks and assess the
distance and location of peaks to genomic features, the Homer function
annotatePeaks was used [403]. This function summarizes the location of peaks
to genomic features (e.g. intergenic, intron, exon, promoter) and identifies
specific genes associated with these peaks. Visualization of genomic distribution
of peaks was performed by ChIPSeeker [404]. Gene ontology analysis was
performed by the Homer function annotatePeaks with the -go option selected.
Motif enrichment analysis was performed by the findMotifsGenome.pl
script of Homer. This analysis scans all peaks within the given peakset for known
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motif consensus sequences to identify peaks that overlap with transcription factor
binding motifs. For motif scanning, region size was set at 200 bp, centered at the
peak summit; that is ±100 bp from the summit of each peak was scanned for
matching sequences to known motifs. The lengths of motifs to be found were set
to 8 bp, 10 bp, and 12 bp. Additionally, the number of unique motifs was limited
to the top 25 enriched. The output of this analysis simply provides the most
enriched motifs and their associated transcription factor. To determine the
location of these motifs, annotatePeaks was used again – the differential peakset
for a given comparison was paired with its motif enrichment dataset to identify
peaks that contained specific motifs.
Results
As a continuation of our investigation into the epigenetic modifications that
occur during B. burgdorferi infection, we performed ATAC-seq to profile structural
changes in chromatin at four infection time points and non-infection control: 24,
48, 72, and 96 hours. Several quality control assessments were performed on
our read files and compared to ENCODE standards
(https://www.encodeproject.org/atac-seq/#standards). Insert size was determined
for each sample. ATAC-seq utilizes a Tn5 transposase, which cleaves DNA in
open chromatin, and as such, the majority of insert sizes will be small fragments,
specifically subnucleosomal <150bp. Approximately 147 bp of DNA wrap around
histones, in which the transposase will cleave and index reads at either end of
the histone – this corresponds to a slight enrichment at 150-200bp. An additional
minor enrichment in insert size is typically seen at di-nucleosome lengths,
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approximately 300-400bp. In all of our samples, this pattern can be seen.
Figure IV-1 shows representative images of these quality control measures.
Additional quality control metrics can be found in Appendix B. In order for gene
transcription to initiate, typically the transcription start site (TSS) is in the open
chromatin configuration. As such, it can be expected that Tn5 accessibility at
TSS’s is enriched at a genome-wide level. ENCODE standards require an
enrichment score > 6; all samples passed except for one technical replicate
within the 96-hour group (#014). Another enrichment criterion assesses the
fraction of reads in peaks (FRiP) – a fraction >0.2 is considered passable. Again,
all samples passed except for the same technical replicate, #014. Mitochondrial
reads and duplicate reads are two concerns that can considerably impact library
complexity and usable reads. ENCODE requires 25 million non-mitochondrial,
non-duplicate reads. Following the removal of these reads, only 8 samples
contained >25 million aligned reads. Nevertheless, while our samples did not
meet all the requirements set by ENCODE, we continued with downstream
analysis.
Peaks were called by MACS2, and differential peak analysis was
performed by DiffBind. As stated in the methods, DiffBind forms a consensus
peakset, which characterizes a consensus peak as being found in at least two
samples. A total of 120,925 unique peaks were found across all samples, of
which 82,910 peaks were found in at least 2 samples and placed within the
consensus peakset for additional analysis. Differential peak analysis by DiffBind
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Figure IV - 1.

Representative quality control metrics.
(A) The insert size of control sample #001 indicating a pattern
associated with ATAC-seq. The Tn5 transposase cleaves open
chromatin, producing fragments of subnucleosomal size (<150 bp).
The transposases will also cleave DNA around mono-nucleosomes,
producing fragments of around 150-200 bp. A second minor
enrichment can be observed at the 300-400 bp range, indicated dinucleosome fragments. The inset graph corresponds to log
transformation of count numbers. (B) Bar graph of fraction of reads in
peaks (FRiP). This is a quality control metric to determine if enrichment
of reads occur within peaks. (C) A bar graph of transcription start site
(TSS) enrichment for each sample. A minimum TSS enrichment score
of 6 is required. (D) TSS enrichment peak graph of sample #001. Peak
enrichment occurs directly above the TSS.
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utilizes DESeq2 to determine significance, and an FDR < 0.05 was determined to
be significant. Infected groups were compared to control and the number of
differential peaks is as follows, while the number of open and closed peaks are in
parentheses (Open : Closed): 24-hour – 25,464 (18,883 : 6,581); 48-hour – 7,266
(7,068 : 198); 72-hour – 3,376 (3,372 : 4); 96-hour – 3,015 (207 : 2,808). This
downward trend in the number of differential peaks indicates that astrocytes are
responding to B. burgdorferi infection much more rapidly than we had initially
expected based on our previous gene expression data. Our previous data,
highlighted in Chapter 3, indicates peak protein production occurring at 72 to
96 hours. However, chromatin accessibility is a requirement prior to gene
expression, thus, finding a maximum peak enrichment for open chromatin at
24 hours would correspond to subsequent increase in gene expression at later
time points. At each subsequent time point, the number of differential peaks
continues to decrease; however, it is interesting to note that while at 24, 48, and
72 hours open chromatin predominates, while at 96 hours, the opposite is found.
Additionally, overlapping analysis, displayed as a Venn diagram in Figure IV-2A,
indicates peaks that are shared amongst each group and peaks that are unique
to each time point. The following number of differential peaks are unique to each
group: 24-Hour – 18535; 48-Hour – 1223; 72-Hour – 1355; 96-Hour – 2022. A
total of 57 differential peaks were found in all groups.
The location of peaks (i.e. accessibility of chromatin) is important to
determine the functional relevance of the changes that occur during infection.
Generally, open chromatin is required near or within the promoter/TSS and exon
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Figure IV - 2.

Differential peak analysis.
(A) A Venn diagram of the number of differential peaks in each
treatment group and those that overlap. The number of unique
peaks of each group can be identified and the number of peaks
shared amongst all groups is shown. (B) Differential peaks of
each group were annotated, and their genomic features mapped
and frequency plotted on a bar graph. 24-hour and 48-hour
groups share similar patterns in genomic features – Intergenic
and Intron regions were more highly enriched compared to
promoter regions. The opposite is observed in 72 and 96-hour
groups. (C) Gene Ontology analysis was performed on
differential peaks; intergenic regions were removed for this
analysis. The top 10 enriched biological processes for each
group are shown. (D) 57 differential peaks were shared among
all four time points. Genomic feature and biological process
analysis was performed on these.
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locations for gene expression, while regulatory elements such as enhancers may
be found in intergenic and intronic regions. Therefore, we sought to determine
the frequency of peak enrichment within specific genomic features, highlighted in
Figure 4-2B. The 24 and 48-hour groups shared similar patterns in genomic
feature enrichment. The majority of peaks were found within intergenic and intron
regions, with the promoter region showing less enrichment. However, at
72-hours, this trend changes, such that the greatest enrichment occurs in the
promoter region, while lower enrichment was found at intergenic and intron
locations. This continues and is in fact elevated in the 96-hour group, with the
promoter regions containing nearly 50% of all peaks. It is important to also note
that this increase in differential peaks at the promoter region corresponds to
closing of accessibility, in which 2,808 out of 3,015 differential peaks were
reduced following infection.
Gene ontology analysis performed by Homer provides insight into
biological processes that are enriched. The top 10 enriched biological processes
of differential peaks for each group and shared peaks are shown in Figure 4-2C.
Multiple biological processes were shared between 24, 48, and 72-hour time
points, including: Anatomical Structure development and morphogenesis,
developmental process, and multicellular organism development. Signaling
processes were found to be enriched within the 24-hour time point that were
subsequently reduced at later time points. These include regulation of cell
communication, regulation of signal transduction, and regulation of signaling. As
many of the functions performed by astrocytes fall under the large umbrella of
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these biological terms such as chemokine and cytokine production, this may
suggest a restructuring of chromatin to promote this activated state. However,
these processes change quite remarkably at the 96-hour time point; instead of
structural and signaling processes, the astrocytes undergo chromatin
rearrangement centered around metabolic and cellular stress. A more concise
picture is found when analyzing peaks that are common amongst all groups.
Biological processes based on these differential peaks indicate astrocytes
undergoing immunological processes that include response to cytokines, immune
cell activation (leukocytes and mast cells), and T cell chemotaxis. Furthermore, in
line with the idea that astrocytes are undergoing subsequent chromatin
restructuring following infection, chromatin and nucleosome assembly was found
to be shared amongst these groups.
Several inflammatory and immune-related genes were found to contain
differential peaks. Table IV-1 indicates genes of interest that were associated
with differential peaks. It is important to note that in the table a negative fold
change corresponds to an open conformation, while a positive fold change
corresponds to a closed conformation. Many of these genes have previously
been associated with B. burgdorferi infection that revolve around an inflammatory
chemokine and cytokine response which function to attract and activate both
innate and adaptive immune cells. In general, these peaks were found to be
enriched towards the open configuration of chromatin and were predominately
found within the earlier time points – 24 and 48-hours. Chemokine C-C motif
ligands (CCLs) and Chemokine C-X-C motif ligands (CXCLs) are common
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Table IV - 1. List of selected peaks and associated genes
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signaling proteins that are released by a wide range of cells. These proteins act
as chemotactic and inflammatory cytokines that aid in the attraction of peripheral
immune cells such as monocytes, T-lymphocytes, and neutrophils. A peak at
CCL2 was found to be enriched within the promoter-TSS region only at the
24-hour time point, which may indicate an increase in gene expression. CCL2
acts as a recruitment factor for monocytes and basophils. Similarly, CCL26, an
inflammatory and eosinophil chemotactic factor, contained an enriched peak only
at the 24-hour time point. Additional immune genes that were unique to the
24-hour group include TLR9, a toll-like receptor that recognizes pathogenassociated molecular patterns (PAMPs), and CXCL17, a chemoattractant for
dendritic cells and monocytes. TLR5 (24, 48, and 72-hour) and TLR6 (48-hour)
were found to be enriched as well throughout multiple time points. CXCL6, a
neutrophilic chemoattractant was also found to be enriched at 24 and 48-hours,
and gene expression has previously been shown to be elevated in astrocytes
[198]. CXCL13, a B lymphocyte chemoattractant that was enriched at both of
these time points, has shown to be an important factor specifically for
neuroborreliosis, as it has been implicated as a possible biomarker for the
neurological condition of Lyme disease [78,79]. In contrast, a reduction at this
CXCL13 region was observed at 96-hours. STAT1 and STAT2 are signal
transducer proteins that act as transcription factors. Both have been observed to
be increased in B. burgdorferi infection studies and play important roles in the
induction of the interferon response [234,236,237]. However, both were only
observed at 24-hours and were enriched in opposite directions – STAT1 had
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enrichment within an intron, STAT2 showed a reduction within the TSS. STAT1
has previously been shown to be important in mediating the inflammatory
response for Lyme carditis, however, it is uncertain the possible impact the
reduction of STAT2 may have within our system [405]. Though it is common for
STAT1 and STAT2 to form a heterodimer, STAT1 has shown to interact with a
wide range of other transcription factors including IRF1, which was shown to be
enriched as well [406,407].
Under the assumption that peak enrichment within the gene corresponds
to gene expression, it appears that at earlier time points, astrocytes elicit an initial
inflammatory response that is later lost. This may indicate a failure in a positive
paracrine feedback loop that may be dependent on the presence of additional
cells and anatomical context as many of these factors function as attractants for
other immune cells. This is evident in co-culture studies of glial cells and neurons
in which the addition of astrocytes and microglia during B. burgdorferi infection
led to an increase in neuronal apoptosis compared to B. burgdorferi infection
only. In the rhesus macaque model, glial cells have been implicated in the onset
and progression of neuroborreliosis due to the secretion of similar chemokine
profiles including CCL2 and CXCL13 [151,283]. It is often observed that in
comparison to more professional immune cells such as microglia, astrocytes do
not produce a large immune and inflammatory response in regards to range and
scale [141,408,409]. However, this seems to underscore the wide repertoire of
supportive functions that astrocytes perform in a context dependent manner and
may shed insight into the loss of inflammatory and immunological genes at later
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time points. G protein-coupled receptor 183 (GPR183) was found to be enriched
at both introns and promoter regions at all time points except 96-hours, in which
the fold-change reversed. The function of GPRs in the context of Lyme disease is
not fully understood, but they have been previously shown to be induced during
infection, including GPR183, and may be associated with subsequent
inflammation [168,410,411].
B. burgdorferi has long been shown to induce the production of matrix
degradative proteins, specifically matrix metalloproteinases (MMP2). The
induction of these proteinases leads to the degradation of the extracellular matrix
such as collagen and fibronectin. These have been shown to play an important
role in the manifestation of many of the inflammatory symptoms of Lyme disease,
including arthritis and neuroborreliosis [161,412–416]. These factors aid in the
dissemination of B. burgdorferi through the breakdown of barriers and lead to the
exacerbation of immune cell invasion. A number of these factors were found to
be enriched, including MMP2 and MMP16 at a number of time points.
Importantly, the two main activators of many of these degradative proteins, PLAU
(urokinase, uPa) and PLAT (tissue plasminogen activator, tPA), were found to be
enriched from 24 to 72 hours. However, in contrast, the principal inhibitor of both
activators, SERPINE1 (plasminogen activator inhibitor-1, PAI-1), was also found
to be enriched at these time points. Furthermore, the receptor for uPA, urokinase
receptor (PLAUR) was found to be reduced at 96-hours. This provides further
evidence of B. burgdorferi induction of host extracellular matrix modulators and
provides insight into the chromatin restructuring that promotes this outcome.
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Motif and Transcription Factor Enrichment
One invaluable aspect of ATAC-seq is the ability to identify specific
transcription factor motif enrichment based on the opening of chromatin. The
Homer package and findgenomemotif function provides detailed enrichment
information of these motifs, their locations, and subsequent annotations of their
respective peaks. As transcription factors can bind and promote the expression
of many genes of a more specific function (e.g. immune regulatory genes), we
can formulate an idea of the mechanisms and expression patterns associated
with our infection groups. Though our previous discussion on differential peaks
were focused on enrichment of genes within the gene body, broadening the
scope of motif enrichment to intergenic regions can provide insight into enhancer
locations and their respective function based on the specific transcription factor
that may bind to it. To this end, we sought to identify the top enriched motifs of
each group, shown in Figure IV-3.
Activator protein 1 (AP-1) is a major transcription factor that regulates the
expression of genes associated with stimuli from cytokines, stress signals, and
infections [417]. AP-1 has been shown to play important roles in cancer, both in
tumorigenesis as well as potential tumor-suppressive functions [418–421]. The
transcription factor has been shown to serve as regulators of the immune
response during bacterial infection, including the mediation of inflammation and
persistence of Chlamydia pneumoniae [422,423]. Furthermore, it plays important
roles in immune cell differentiation [424–426]. Activation of T cells has been
shown to be dependent on a well organized opening and closing of chromatin,
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Figure IV - 3.

Motif enrichment analysis of differential peaks.
Motif enrichment analysis was performed on the differential
peaksets for each group and shared peaks. The top 5 enriched
motifs for each group are shown along with their associated
transcription factor (TF). Only one motif for the shared peakset
was enriched.
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and as such, AP-1 has been identified as a required and predominant
transcription factor that directs this chromatin remodeling [427]. In astrocytes,
AP-1 serves to activate several pathways that include the induction of GFAP
production which is a marker of astrogliosis and providing neuroprotective effects
[164,428,429]. AP-1 has also been shown to play a role in MAPK and STAT
pathways which have been shown to be required for the induction of MMPs
(which commonly contain AP-1 motifs) during B. burgdorferi infection [430]. This
transcription factor has a wide range of functions that generally regulate immune
and stress responses to a number of stimuli, and such functions seem to have
conflicting and opposite effects. An important aspect of AP-1 is that it is
comprised of a heterodimer that is predominately formed by proteins of the FOS
(c-FOS, FOSB, FOSL1 (Fra1), FOSL2 (Fra2)), JUN (c-Jun, JunB, JunD), and
ATF (ATF1-7) families, and to a lesser extent JDP (JDP-1, JDP-2). These
proteins all share a common basic leucine zipper domain (bZIP domain) that
allows them to dimerize with one another. Additionally, due to this conservation in
structure, the motif binding sequences share many similarities. However, minor
differences in binding affinity and gene activation properties highlight differential
phenotypic outcomes.
When motif enrichment analysis was performed on differential peaks of
each time point, including peaks shared between all four groups, the top enriched
motif in each group belonged to a member of the AP-1 transcription factor family.
Furthermore, in multiple instances, the scale of difference between the top
enriched and second most enriched motif was an order of magnitude in regards
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to significance – 24-hour: JunB 1e-4044, RUNX 1e-294; 48-hour: ATF3 1e-1308,
RUNX2 1e-100. The motif for JunB was also the most enriched at 72-hours, and
Fra1 was shown to be the top motif for 96-hours. The only motif that was not
flagged as a possible false positive within the group of shared peaks was the
motif for AP-1. These motifs are highlighted in Figure 4-3, and the degree of
enrichment can be inferred by the p-value as well as the percent of targets found
vs the percent of background. The relevance of JunB within our experimental
model of Lyme disease is highlighted in studies showing its role in the modulation
of inflammation and its key function in the development and activation of immune
cells. In T-cells, JunB is essential for the development of Th17 cells and
regulatory T cells through the promotion of IL-2, and is required for the proper
regulation of Th2 cell-specific cytokine profile [425,431]. In an experiment
involving the stimulation of macrophage activation through LPS, JunB was
confirmed to be a required factor necessary for the full expression of IL-1β, an
inflammatory cytokine that highlights macrophage activation and was also
observed to be increased in B. burgdorferi infected astrocytes [198,432]. Though
its role in Lyme disease is yet to be fully elucidated, it has been previously shown
to be induced in macrophages infected with B. burgdorferi [411]. However, in
contrast to this, our differential peak analysis indicates that at 24-hours, JunB
shows a Log2FC of 0.44 at the promoter-TSS region, corresponding to a closing
of chromatin, which was observed in later time points. Two conclusions can be
drawn from this. If we assume that this correlates to a reduction in JunB
transcription, it may underscore the closing of inflammatory genes at later time
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points, inferred by the lack of differential opening. However, it is important to
reiterate the similarities of motif consensus sequence between the members of
the AP-1 family. As such, the Homer program places these proteins under the
same or similar motifs, in which they are further ranked by matching score.
However, in the case of 24-hour time point, JunB, BATF, and Atf3 had identical
scores, but were ranked as such under the JunB enrichment heading. The
reason I make this clarification is because BATF3, a member of the BATF/Atf
family, was found to have a Log2FC -0.39 at 24-hours within the promoter-TSS
region, corresponding to an open configuration. This continued into 48-hours
(-0.51) and 72-hours (-0.52) at this same peak and at additional intergenic
regions. This slight distinction may shed light onto the expression of transcription
factors themselves as well as their impact on gene transcription. This is again
highlighted at 48-hour motif enrichment, in which the top motif corresponds to
Atf3. The BATF/Atf family share similarities in function to Jun in regard to the
regulation of immunity and inflammation. Atf3 has shown to negatively regulate
pro-inflammatory cytokine production and its expression is elevated during the
activation of several TLRs in macrophages [433–435]. Similar motif profiles are
seen at 72 and 96-hours and suggest a complex mechanism of the regulation of
inflammation. At this point, without direct gene expression data to overlap with
our ATAC-seq data, it is difficult to expand on the functional outcomes that may
be occurring, but we are able to provide potential mechanistic routes that may
explain and suggest astrocyte dysregulation that may be brought upon by the
alternation of multiple AP-1 motif openings and closings.
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Discussion
At present, our current study has produced insight into the chromatin
restructuring of astrocytes in response to B. burgdorferi. We have shown that at
earlier time points that inflammatory chemokines and interferon-related genes
show an increase in opening that may close at later time points. Through
biological process enrichment, we observed large changes in anatomical
restructuring and cell communication, overlapping with the broad roles that
astrocytes are known to undertake – this is also highlighted in the astrocyte
infection study with B. burgdorferi performed by the Brissette lab, which indicated
differentially expressed genes that cover a wide range of biological processes
[198]. Of interest for future studies is the drastic change between the earlier and
later time points, notably the shift to promoter enrichment, away from potential
enhancer regions, and a flip in differential peak enrichment at 96-hours.
However, at the 96-hour time point, it is important to take into consideration the
quality of reads, in which at least one replicate (#014) performed far worse than
other samples. However, through combining the differential peaks and
investigating those that are shared amongst all groups, we were able to get
insight into core functional outcomes that may be taking place. When observing
these peaks, a common biological process of the immune response was seen.
This is highlighted by leukocyte and mast cell activation and response to cytokine
stimulus. Furthermore, to lend credibility to the chromatin restructuring that takes
place following infection, the biological processes of nucleosome and chromatin
assembly were enriched.
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Our investigation into chromatin restructuring as a potential marker and
mechanism for neuroborreliosis and PTLDS stemmed from a lack of evidentiary
findings and further interest was piqued by the observation of chromatin
assembly processes being enriched in the aforementioned astrocyte-Borrelia
paper by Casselli et al. From this, our initial experimental design sought to
perform ATAC-seq to obtain a global, genome-wide view of the changes in
chromatin structure. Additionally, based on goals, our methodology was to
correlate these changes to gene expression through RNA-seq and to determine
specific histone modifications as a mechanistic outcome. At the onset of this
project, we had set up our experiments such that we collected enough astrocytes
to be used for RNA-seq and ChIP-PCR or ChIP-seq to find direct correlations to
changes in chromatin structure. Unfortunately, we had encountered numerous
technical limitations during the ATAC-seq procedure. Not shown are the multiple
infection experiments and subsequent ATAC-seq experiments performed on
Illumina Miseq instruments to determine the efficacy of the procedure.
Eventually, we were able to meet quality control prerequisites for greater
coverage sequencing on Illumina HiSeq machines. However, as shown, many
samples did not meet the final ENCODE data standards. With this in mind, and
though the depth of coverage was not optimal, we were able to garner brief
insight into alternative mechanistic routes of the astrocytic response to B.
burgdorferi. It is hopeful that with further investigation into bacterial infections,
including Lyme disease, and their impacts as epimutagens, that a more explicit
pathogenesis of neuroborreliosis and PTLDS will soon be revealed.
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CHAPTER V
DISCUSSION
Summary of Findings, Limitations, and Future Directions
At the beginning of my graduate career and with the Borrelia burgdorferi
expertise of Dr. Catherine Brissette and neuroscience expertise of Dr. Watt, I had
sought to investigate and expound two major gaps in knowledge that center on
the neurological effects of Lyme disease. To date there is no clear evidence on
the route of entry for B. burgdorferi into the CNS. Additionally, once within the
CNS, the pathogenesis of the neurological effects of PTLDS is unknown. Though
there are multiple competing theories within the field, we sought to investigate
alternative and novel hypotheses for these questions.
In Chapter II, our experiments investigated an alternative route of entry
into the CNS aside from the blood-brain barrier. Though previous research had
been done on endothelial cells simulating this barrier, further methods on the
dissemination into the CNS have yet to be performed. This uncertainty is further
exacerbated by the logical conclusion that if B. burgdorferi enters the CNS via
the blood-brain barrier, it would therefore be inferred that the bacteria will be
commonly found within the brain parenchyma. However, due to obvious
limitations in performing brain biopsies on living humans, and the fact that Lyme
disease is rarely fatal preventing post-mortem analysis, this outcome is currently
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unanswered. In defense of this approach, there is some evidence to suggest
invasion of the parenchyma through the use of animal models, but such data is
limited. Considering this, we sought to follow clinical evidentiary findings that
would lead to a better understanding of this phenomenon. As stated previously,
B. burgdorferi is able to enter the CNS – this is evident by lumbar puncture and
direct culturing of the bacteria from the CSF of neuroborreliosis patients.
Furthermore, it is well-known that the choroid plexus is highly implicated in
bacterial and viral infections in allowing passage of the pathogen or peripheral
immune cells directly into the CSF as the choroid plexus epithelium composes
the Blood-CSF barrier. We therefore sought to use this as a system to determine
the impact of B. burgdorferi on cultured choroid plexus epithelium cells.
Our findings had indicated what we initially hypothesized and what is in
line with current research – a robust inflammatory and immune response that is
produced by these epithelial cells. Furthermore, as observed in other infections,
a common cytokine profile of the epithelium was that of secreted factors for the
chemotaxis of peripheral immune cells. At the onset of our experiments, it was
unknown how barrier related genes would be altered. As this was performed in
vitro the choroid plexus epithelial cells lacked important physiological and
anatomical context that may inhibit findings into barrier properties. However, to
our surprise, we found a number of genes of barrier components and regulatory
and structural factors to be downregulated. An extrapolation into an in vivo
context would suggest that the integrity of the blood-CSF barrier may be
compromised. Additionally, our downstream pathway analysis supported these
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conclusions. Based on these promising results, investigating this system within
an in vivo model is our aim for future experiments.
In Chapters III and IV, we had sought to investigate a novel mechanism
behind PTLDS. Current hypotheses include the establishment of a low and
undetectable infection of B. burgdorferi even after antibiotic treatment, and the
amber hypothesis which states that the dead bacteria or debris from the bacteria
is sufficient to produce a continual inflammatory response. The former hypothesis
has not been well confirmed, while the later has shown promising results in which
cell components of B. burgdorferi have been shown to elicit an immune
response. Both ideas revolve around a persistent inflammatory state that would
lead to deleterious outcomes. With this in mind, we sought to investigate
mechanisms that would allow for inflammatory and immune genes to remain in a
high transcript state that would persist after infection had been cleared. Through
previous work of the epimutagen properties of other bacterial infections, we
aimed to apply this to Lyme disease, specifically the neurological aspects of
PTLDS. Due to the important and wide scope of astrocytic functions, we aimed to
investigate the impact of B. burgdorferi infection of the astrocyte methylome and
chromatin landscape.
In Chapter III, investigating the impact on DNA methylation, we ran into a
major technical limitation within our methodology. As our primary human samples
were obtained from three different individuals, our variability amongst replicates
was so great that no differential methylation states were found. However, through
the pooling of specific infection groups, we were able to gain limited findings that
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included changes in methylation at sites of genes whose functions involved cell
signaling and modulation of immune response. These genes were specifically
involved in extracellular glutamate modulation and downregulation of NF-κB.
In Chapter IV, we investigated the chromatin landscape in response to
B. burgdorferi through the use of ATAC-seq. Though we had altered our
methodology to take into account the variability of primary samples, we ran into a
number of technical issues that limited our access to high coverage sequencing
data. However, our data was sufficient to provide a clear indication into the
changes in that are occurring within astrocytes in response to infection. We
observed large initial change in chromatin accessibility that predominately lead to
open states throughout the genome. Interestingly, at later time points, these
enriched regions continued to reduce in number. Many of the initial differential
peaks were found to be involved in innate immunity, specifically cell signaling
through cytokine production. However, looking at peaks shared amongst all time
points, we were able to clearly see that immune cell activation and chromatin
restructuring was a shared characteristic between all groups. In support of this,
motif enrichment analysis indicated AP-1 transcription factor motifs were highly
enriched across each group. Our conclusion indicates that an initial innate
immune response is produced by astrocytes, that may not persist at later time
points; however, based on motif analysis, this may just indicate a change gene
profile that still remains within the inflammatory and immune response group. Our
experiments were started with the expressed intent to provide correlative data of
gene expression and histone modifications to our ATAC-seq data. However, due
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to limitations in the ATAC-seq procedure, such analysis was not undertaken. Our
future directions would aim to continue this line of thought.
Conclusion
B. burgdorferi has been around for thousands of years, inflicting pain and
suffering in countless individuals, and though research has made great advances
in providing medical care of patients, there are still many avenues of the disease
to uncover. For the five years that span my graduate career, I had set out to add
to the wealth of information within the Lyme disease field, to contribute some
helpful piece of knowledge in understanding this disease. Although some
experiments were met with limitations, I have felt I have met this goal to a
degree. It is hopeful that with the gain in publicity, understanding of the disease
will becoming even more widespread within the public. Through this education,
we can ameliorate many aspects of the disease through simple administration of
antibiotics. My research had focused on the aspect of the disease in which there
is high correlation between a failure in timely antibiotic treatment and the onset of
late stage and persistent symptoms – the effects of neuroborreliosis and PTLDS
can be drastic, lowering the quality of life for a lifetime, and unfortunately at this
stage, there are no current therapeutics for patients. It is my anticipation that
future research will be successful in uncovering these mechanisms and provide
treatment options for the endless number of patients who suffer from Lyme
disease.
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APPENDIX A

Table 1

Full list of significant differentially expressed genes for choroid plexus
epithelial cells infected with B. burgdorferi – Chapter 2

Gene Names

Base Mean

log2FoldChange

padj
7.63E-18

Control
Mean
93.654

Treated 48
Mean
802.687
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448.17

1.9238
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764.51
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7.87E-09
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1.4001

1.51E-10

3453.899

13239.393

CCL5

430.80

1.3553

4.67E-09
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IFITM1
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41027.568

IFIT3
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17978.807
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2.80E-08

2287.800

5813.465

HERC5

188.00

1.0886

2.14E-07
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CD38

311.03

0.8235

8.32E-05

205.946

416.114
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APPENDIX B

Figure Appendix B – 1:

TSS enrichment – Chapter IV
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Figure Appendix B – 2:

PCR Bottleneck Coefficient – Chapter IV

Appendix B
pg. 2

Figure Appendix B – 3:

Percent of duplicate and mitochondrial reads
– Chapter IV
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